Document:

EX-10.1

 Exhibit 10.1 

CONSTELLATION PHARMACEUTICALS, INC. 

FIFTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

March 22, 2018 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
			
	 1.
	 	 CERTAIN DEFINITIONS
	  	 	1	 
			
	 2.
	 	 REGISTRATION RIGHTS
	  	 	7	 
				
		 	 2.1
	  	 Required Registrations
	  	 	7	 
				
		 	 2.2
	  	 Incidental Registration
	  	 	8	 
				
		 	 2.3
	  	 Registration Procedures
	  	 	10	 
				
		 	 2.4
	  	 Allocation of Expenses
	  	 	11	 
				
		 	 2.5
	  	 Indemnification and Contribution
	  	 	12	 
				
		 	 2.6
	  	 Other Matters with Respect to Underwritten Offerings
	  	 	14	 
				
		 	 2.7
	  	 Information by Holder
	  	 	14	 
				
		 	 2.8
	  	 “Lock-Up” Agreement; Confidentiality of
Notices
	  	 	14	 
				
		 	 2.9
	  	 Limitations on Subsequent Registration Rights
	  	 	15	 
				
		 	 2.10
	  	 Rule 144 Requirements
	  	 	15	 
				
		 	 2.11
	  	 Transfer of Registrable Shares
	  	 	16	 
				
		 	 2.12
	  	 Termination
	  	 	17	 
			
	 3.
	 	 RIGHT OF FIRST REFUSAL
	  	 	17	 
				
		 	 3.1
	  	 Rights of Purchasers to Acquire Offered Securities
	  	 	17	 
				
		 	 3.2
	  	 Termination
	  	 	20	 
			
	 4.
	 	 AFFIRMATIVE COVENANTS
	  	 	20	 
				
		 	 4.1
	  	 Payment of Taxes and Trade Debt
	  	 	20	 
				
		 	 4.2
	  	 Maintenance of Insurance
	  	 	20	 
				
		 	 4.3
	  	 Preservation of Corporate Existence
	  	 	20	 
				
		 	 4.4
	  	 Compliance with Laws
	  	 	21	 
				
		 	 4.5
	  	 Keeping of Records and Books of Account
	  	 	21	 
				
		 	 4.6
	  	 Maintenance of Properties, etc
	  	 	21	 
				
		 	 4.7
	  	 Inspection and Observation
	  	 	21	 
				
		 	 4.8
	  	 Financial Statements and Other Information
	  	 	22	 
				
		 	 4.9
	  	 Material Changes and Litigation
	  	 	23	 
				
		 	 4.10
	  	 Agreements with Employees; Options
	  	 	23	 
				
		 	 4.11
	  	 Board of Directors
	  	 	24	 
				
		 	 4.12
	  	 Related Party Transactions
	  	 	24	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	Page	 
				
		 	 4.13
	  	 Reservation of Common Stock
	  	 	25	 
				
		 	 4.14
	  	 International Investment and Trade in Services Survey Act
	  	 	25	 
				
		 	 4.15
	  	 Standard of Conduct
	  	 	25	 
				
		 	 4.16
	  	 Termination of Covenants
	  	 	25	 
				
		 	 4.17
	  	 Use of Name
	  	 	25	 
				
		 	 4.18
	  	 Right to Conduct Activities
	  	 	26	 
			
	 5.
	 	 CONFIDENTIALITY
	  	 	26	 
			
	 6.
	 	 TRANSFERS OF RIGHTS; CALCULATION OF SHARE NUMBERS
	  	 	27	 
				
		 	 6.1
	  	 Transfer of Rights
	  	 	27	 
				
		 	 6.2
	  	 Calculation of Share Numbers
	  	 	27	 
			
	 7.
	 	 GENERAL
	  	 	27	 
				
		 	 7.1
	  	 Severability
	  	 	27	 
				
		 	 7.2
	  	 Specific Performance
	  	 	27	 
				
		 	 7.3
	  	 Governing Law
	  	 	28	 
				
		 	 7.4
	  	 Notices
	  	 	28	 
				
		 	 7.5
	  	 Complete Agreement
	  	 	28	 
				
		 	 7.6
	  	 Amendments and Waivers
	  	 	28	 
				
		 	 7.7
	  	 Pronouns
	  	 	29	 
				
		 	 7.8
	  	 Counterparts; Facsimile Signatures
	  	 	29	 
				
		 	 7.9
	  	 Section Headings and References
	  	 	29	 

  
 -ii- 

 CONSTELLATION PHARMACEUTICALS, INC. 

FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This Agreement dated as of March 22, 2018 is entered into by and among Constellation Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), and the individuals and entities listed on Exhibit A attached hereto (the “Purchasers”). 

Recitals 
 WHEREAS,
certain of the Purchasers are parties to that certain Fourth Amended and Restated Investor Rights Agreement, dated as of September 13, 2016, by and among the Company and such Purchasers (the “Series
E-1 Investor Rights Agreement”); 
 WHEREAS, the Corporation and certain of the Purchasers (the
“Series F Purchasers”) have entered into that certain Series F Convertible Preferred Stock Purchase Agreement (the “Series F Preferred Stock Purchase Agreement”), in connection with the issuance and sale by the Company to the
Series F Purchasers of shares of the Company’s Series F Convertible Preferred Stock, $0.001 par value per share (“Series F Preferred Stock”); 

WHEREAS, the Series F Purchasers have required, as a condition to the purchase of the Series F Preferred Stock, pursuant to the Series F
Preferred Stock Purchase Agreement that they be granted rights with respect to such shares regarding (i) the registration of shares of capital stock of the Company under the Securities Act (as defined below) and (ii) certain
Purchasers’ rights of first refusal with respect to certain issuances of securities of the Company; 
 WHEREAS, pursuant to
Section 7.6 of the Series E-1 Investor Rights Agreement, amendment of the Series E-1 Investor Rights Agreement requires the written consent of the Company and
Purchasers (as defined in the Series E-1 Investor Rights Agreement) holding Shares (as defined in the Series E-1 Investor Rights Agreement) representing at least a
majority of the voting power of all Shares (as defined in the Series E-1 Investor Rights Agreement) then held by Purchasers (assuming the exercise of all Warrants (as defined in the Series E-1 Investor Rights Agreement) for shares of Common Stock); and 
 WHEREAS, the signatories of this
Agreement hold the requisite number of Shares (as defined in the Series E-1 Investor Rights Agreement) to effect this amendment and restatement of the Series E-1
Investor Rights Agreement; 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties
hereto agree that the Series E-1 Investor Rights Agreement be, and hereby is, amended and restated to read as follows: 

1. Certain Definitions. 

As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliated Party” means, with respect to any Purchaser, any person or entity which, directly or indirectly, controls, is
controlled by or is under common control with such Purchaser, including, without limitation, any general partner, officer or director of such Purchaser and any venture capital fund now or hereafter existing which is controlled by one or more general
partners of, or shares the same management company as, such Purchaser. 

  
 1 

 “Available Undersubscription Amount” means the difference between the total of
all of the Basic Amounts available for purchase by Major Investors pursuant to Section 3.1 and the Basic Amounts subscribed for pursuant to Section 3.1. 

“Basic Amount” means, with respect to a Major Investor, its pro rata portion of the Offered Securities determined by
multiplying the number of Offered Securities by a fraction, the numerator of which is the aggregate number of shares of Common Stock issued or issuable upon conversion of all Shares then held by such Major Investor, and the denominator of which is
the total number of shares of Common Stock then outstanding (giving effect to the conversion into Common Stock of all outstanding shares of convertible preferred stock, and all shares of Common Stock issuable upon the exercise of outstanding
Warrants). 
 “Board of Directors” means the Board of Directors of the Company. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Commission” means the Securities and Exchange Commission, or any other federal agency at the time administering the
Securities Act. 
 “Common Stock” means the common stock, $0.0001 par value per share, of the Company. 

“Company” has the meaning ascribed to it in the introductory paragraph hereto. 

“Company Sale” means: (a) a merger or consolidation in which (i) the Company is a constituent party, or (ii) a
Company Subsidiary is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except in the case of either clause (i) or (ii) any such merger or consolidation involving the Company or a
Company Subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock which represent, immediately
following such merger or consolidation, more than 50% by voting power of the capital stock of (A) the surviving or resulting corporation or (B) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation
immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; (b) the sale, lease, transfer, exclusive license or other disposition with or to a Public Company, in a single transaction or
series of related transactions, by the Company or a Company Subsidiary of all or substantially all the assets of the Company and the Company Subsidiaries taken as a whole (except where such sale, lease, transfer, exclusive license or other
disposition is to a wholly owned Company Subsidiary); or (c) the sale or transfer, in a single transaction or series of related transactions, by the stockholders of the Company of more than 50% by voting power of the then-outstanding capital
stock of the Company to any Public Company. 

  
 2 

 “Company Subsidiary” means any corporation, partnership, trust, limited
liability company or other non-corporate business enterprise in which the Company (or another Company Subsidiary) holds stock or other ownership interests representing (a) more than 50% of the voting
power of all outstanding stock or ownership interests of such entity or (b) the right to receive more than 50% of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a
liquidation or dissolution of such entity. 
 “Confidential Information” means any information that is labeled as
confidential, proprietary or secret which a Purchaser obtains from the Company pursuant to financial statements, reports and other materials provided by the Company to such Purchaser pursuant to this Agreement or pursuant to visitation or inspection
rights granted hereunder. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor federal
statute, and the rules and regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 

“Indemnified Party” means a party entitled to indemnification pursuant to Section 2.5. 

“Indemnifying Party” means a party obligated to provide indemnification pursuant to Section 2.5. 

“Initial Public Offering” means the initial underwritten public offering of shares of Common Stock pursuant to an effective
Registration Statement. 
 “Initiating Holders” shall mean any Purchaser or Purchasers who in the aggregate hold more than
fifty percent (50%) of the outstanding Registrable Shares. 
 “Major Investor” shall mean, collectively, the Non-Strategic Major Investors and the Strategic Major Investors. 
 “Non-Strategic Major Investor” shall mean any Purchaser, other than a Strategic Major Investor, who continues to hold an aggregate of at least 500,000 Shares (subject to appropriate adjustment for stock
splits, stock dividends, recapitalizations, and similar events occurring after the date of this Agreement). 
 “Notice of
Acceptance” means a written notice from a Major Investor to the Company containing the information specified in Section 3.1(b). 

“Offer” means a written notice of any proposed or intended issuance, sale or exchange of Offered Securities containing the
information specified in Section 3.1(a). 
 “Offered Securities” means (a) any shares of its Common Stock,
(b) any other equity securities of the Company, including, without limitation, shares of preferred stock, (c) any option, warrant or other right to subscribe for, purchase or otherwise acquire any equity securities of the Company, or
(d) any debt securities convertible into capital stock of the Company. 

  
 3 

 “Other Holders” means holders of securities of the Company (other than
Purchasers) who are entitled, by contract with the Company, to have securities included in a Registration Statement. 
 “Preferred
Director” means a member of the Board of Directors: (a) designated solely by The Column Group, LP, Third Rock Ventures, L.P., Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively,
“Venrock Funds”), or (b) holders of a majority of the outstanding Series F Preferred Shares subject to approval by the Board of Directors, each pursuant to that certain Fifth Amended and Restated Stockholders’
Voting Agreement, dated of even date herewith, by and among the Company and the Stockholders (as defined therein), as may amended or restated from time to time. 

“Preferred Shares” means the Series A Preferred Shares, Series B Preferred Shares, Series D Preferred Shares, Series E
Preferred Shares, Series E-1 Preferred Shares and Series F Preferred Shares. 

“Prospectus” means the prospectus included in any Registration Statement, as amended or supplemented by an amendment or
prospectus supplement, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

“Public Company” means any company subject to the reporting provisions of the Exchange Act. 

“Qualified IPO” means an Initial Public Offering prior to which or in connection with which all outstanding Preferred Shares
have been or will be converted to Common Stock. 
 “Purchaser” has the meaning ascribed to it in the introductory paragraph
hereto. 
 “Refused Securities” means those Offered Securities as to which a Notice of Acceptance has not been given by the
Major Investors pursuant to Section 3.1. 
 “Registrable Shares” means (a) the shares of Common Stock issued or
issuable upon conversion of the Shares, (b) any other shares of Common Stock, and any shares of Common Stock issued or issuable upon the conversion or exercise of any other securities, acquired by the Purchasers pursuant to Section 3 of
this Agreement, the Series F Preferred Stock Purchase Agreement, or the Right of First Refusal and Co-Sale Agreement, as each may be amended and/or restated from time to time, and (c) any other shares of
Common Stock issued in respect of such shares (because of stock splits, stock dividends, reclassifications, recapitalizations or similar events); provided, however, that shares of Common Stock which are Registrable Shares shall cease
to be Registrable Shares (i) upon any sale pursuant to a Registration Statement or Rule 144 under the Securities Act or (ii) upon any sale in any manner to a person or entity which is not entitled, pursuant to Section 6, to the
rights under this Agreement or (iii) at such time, following an Initial Public Offering, as they become eligible for sale pursuant to Rule 144(b)(1)(i) under the Securities Act. Wherever reference is made in this Agreement to a request or
consent of holders of a certain percentage of Registrable Shares, the determination of such percentage shall include shares of Common Stock issuable upon conversion of the Shares (including Shares issuable upon the exercise of outstanding Warrants)
even if such conversion has not been effected. 

  
 4 

 “Registration Expenses” means all expenses incurred by the Company in complying
with the provisions of Section 2, including, without limitation, all registration and filing fees, exchange listing fees, printing expenses, fees and expenses of counsel for the Company, fees and expenses of one special counsel selected by the
Selling Stockholders to represent the Selling Stockholders, state Blue Sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding underwriting discounts, selling commissions and the
fees and expenses of Selling Stockholders’ own counsel (other than the special counsel selected to represent all Selling Stockholders). 

“Registration Statement” means a registration statement filed by the Company with the Commission for a public offering and
sale of securities of the Company (other than a registration statement on Form S-8 or Form S-4, or their successors, or any other form for a similar limited purpose, or
any registration statement covering only securities proposed to be issued in exchange for securities or assets of another corporation). 

“Right of First Refusal and Co-Sale Agreement” means the Fifth Amended and Restated
Right of First Refusal and Co-Sale Agreement, dated of even date herewith, by and among the Company and the Purchasers (as defined therein) and the Founders (as defined therein). 

“Rule 144A Information” has the meaning ascribed to it in Section 2.11(c) hereto. 

“Second Series B Purchase Agreement” means the Second Series B Preferred Stock and Warrant Purchase Agreement, dated
May 24, 2011, by and between the Company and the Purchasers listed on Exhibit A thereto. 
 “Securities Act”
means the Securities Act of 1933, as amended, or any successor federal statute, and the rules and regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 

“Selling Stockholder” means any Purchaser owning Registrable Shares included in a Registration Statement. 

“Series A Preferred Shares” means the shares of Series A Convertible Preferred Stock, $0.001 par value per share, of the
Company acquired by certain of the Purchasers pursuant to the Series A Convertible Preferred Stock Purchase Agreement, dated as of April 16, 2008, by and among the Company and the Purchasers (as defined therein). 

“Series B Preferred Shares” means the shares of Series B Convertible Preferred Stock, $0.001 par value per share, of the
Company acquired by certain of the Purchasers pursuant to (i) the Series B Convertible Preferred Stock Purchase Agreement, dated as of May 24, 2010, by and among the Company and the Purchasers (as defined therein) and (ii) the Second
Series B Purchase Agreement. 

  
 5 

 “Series D Preferred Shares” means the shares of Series D Convertible Preferred
Stock, $0.001 par value per share, of the Company acquired by certain of the Purchasers pursuant to the Series D Convertible Preferred Stock Purchase Agreement, dated as of August 5, 2014, by and among the Company and the Purchasers (as defined
therein). 
 “Series E Preferred Shares” means the shares of Series E Convertible Preferred Stock, $0.001 par value per
share, of the Company acquired by certain of the Purchasers pursuant to the Series E Convertible Preferred Stock Purchase Agreement, dated as of November 30, 2015, by and among the Company and the Purchasers (as defined therein). 

“Series E-1 Investor Rights Agreement” has the meaning ascribed to it in the
recitals hereto. 
 “Series E-1 Preferred Shares” means the shares of Series E-1 Convertible Preferred Stock, $0.001 par value per share, of the Company acquired by certain of the Purchasers pursuant to the Series E-1 Convertible Preferred Stock
Purchase Agreement, dated as of September 13, 2016, by and among the Company and the Purchasers (as defined therein). 

“Series F Preferred Stock Purchase Agreement” has the meaning ascribed to it in the recitals hereto.

 “Series F Preferred Shares” means the shares of Series F Preferred Stock issued under the Series F Preferred Stock
Purchase Agreement. 
 “Series F Preferred Stock” has the meaning ascribed to it in the recitals hereto. 

“Series F Purchasers” has the meaning ascribed to it in the recitals hereto. 

“Shares” means the Series A Preferred Shares, the Series B Preferred Shares, the Series D Preferred Shares, the Series E
Preferred Shares, the Series E-1 Preferred Shares, the Series F Preferred Shares, and the shares of Common Stock issuable upon exercise of the Warrants. 

“Strategic Major Investor” shall mean any Purchaser that (i) is, or is investing on behalf of, a
pharmaceutical, biotechnology or medical device company and (ii) is listed on Exhibit B hereto, so long as the investor continues to hold an aggregate of at least 500,000 Shares (subject to appropriate adjustment for stock splits,
stock dividends, recapitalizations, and similar events occurring after the date of this Agreement). 
 “Undersubscription
Amount” means, with respect to a Major Investor, any additional portion of the Offered Securities attributable to the Basic Amounts of other Major Investors as such Major Investor indicates it will purchase or acquire should the other Major
Investors subscribe for less than their Basic Amounts. 
 “Warrants” means the warrants to purchase Common Stock issued
pursuant to the Second Series B Purchase Agreement. 

  
 6 

 2. Registration Rights. 

2.1 Required Registrations. 

(a) At any time after the earlier to occur of (i) five years after the date of this Agreement and (ii) six months after the closing
of an Initial Public Offering, an Initiating Holder or Initiating Holders may request, in writing, that the Company effect a registration on Form S-1 (or any successor form) of Registrable Shares having
an aggregate value of at least $5,000,000 (based on the market price or fair value as determined by the Board of Directors in its sole discretion on the date of such request). 

(b) At any time after the Company becomes eligible to file a Registration Statement on Form S-3
(or any successor form relating to secondary offerings), an Initiating Holder or Initiating Holders or any Purchaser or Purchasers that in the aggregate hold(s) Registrable Shares having an aggregate value of at least $25 million may request,
in writing, that the Company effect the registration on Form S-3 (or such successor form), of Registrable Shares having an aggregate value of at least $1,000,000 (based on the public market price on the
date of such request). 
 (c) Upon receipt of any request for registration pursuant to this Section 2, the Company shall promptly give
written notice of such proposed registration to all other Purchasers. Such Purchasers shall have the right, by giving written notice to the Company within 30 days after the Company provides its notice, to elect to have included in such registration
such of their Registrable Shares as such Purchasers may request in such notice of election, subject in the case of an underwritten offering to the terms of Section 2.1(d). Thereupon, the Company shall, as expeditiously as possible, use
commercially reasonable efforts to effect the registration on an appropriate registration form of all Registrable Shares which the Company has been requested to so register; provided, however, that in the case of a registration requested under
Section 2.1(b), the Company will only be obligated to effect such registration on Form S-3 (or any successor form). 

(d) If the Initiating Holders intend to distribute the Registrable Shares covered by their request by means of an underwriting, they shall so
advise the Company as a part of their request made pursuant to Section 2.1(a) or (b), as the case may be, and the Company shall include such information in its written notice referred to in Section 2.1(c). In such event, (i) the right
of any other Purchaser to include its Registrable Shares in such registration pursuant to Section 2.1(a) or (b), as the case may be, shall be conditioned upon such other Purchaser’s participation in such underwriting on the terms set forth
herein, and (ii) all Purchasers including Registrable Shares in such registration shall enter into an underwriting agreement upon customary terms with the underwriter or underwriters managing the offering. If any Purchaser who has requested
inclusion of its Registrable Shares in such registration as provided above disapproves of the terms of the underwriting, such Purchaser may elect, by written notice to the Company, to withdraw its Registrable Shares from such Registration Statement
and underwriting. If the Company desires that any officers or directors of the Company holding securities of the Company be included in any registration for an underwritten offering requested pursuant to Section 2.1 or if Other Holders request
such inclusion, the Company may include the securities of such officers, directors and Other Holders in such registration and underwriting on the terms set forth herein applicable to the Purchasers. If the managing underwriter advises the Company in
writing that marketing factors require a limitation on the number of shares to be 

  
 7 

 
underwritten, the shares held by officers or directors of the Company and by Other Holders (other than Registrable Shares) shall be excluded from such Registration Statement and underwriting to
the extent deemed advisable by the managing underwriter, and if a further reduction of the number of shares is required, the number of shares that may be included in such Registration Statement and underwriting shall be allocated among all
Purchasers requesting registration in proportion, as nearly as practicable, to the respective number of Registrable Shares held by them on the date of the request for registration made by the Initiating Holders pursuant to Section 2.1(a) or
(b), as the case may be. If any such stockholder would thus be entitled to include more shares than such stockholder requested to be registered, the excess shall be allocated among other participating stockholders pro rata in the manner described in
the preceding sentence. Notwithstanding the foregoing, no such reduction shall reduce the value of the Registrable Shares of the Initiating Holders included in such registration below twenty five percent (25%) of the total value of securities
included in such registration, unless such offering is the Company’s Initial Public Offering and such registration does not include shares of any other selling stockholders. If the managing underwriter has not limited the number of Registrable
Shares or other securities to be underwritten, the Company may include securities for its own account in such registration if the managing underwriter so agrees and if the number of Registrable Shares and other securities which would otherwise have
been included in such registration and underwriting will not thereby be limited. 
 (e) The Company shall not be required to effect more
than three registrations pursuant to Section 2.1(a) or more than two registrations in any twelve-month period pursuant to Section 2.1(b). In addition, the Company shall not be required to effect any registration within six months after the
effective date of the Registration Statement relating to the Initial Public Offering. For purposes of this Section 2.1(e), a Registration Statement shall not be counted until such time as such Registration Statement has been declared effective
by the Commission (unless the Initiating Holders withdraw their request for such registration (other than as a result of information concerning the business or financial condition of the Company which is made known to the Purchasers after the date
on which such registration was requested) and elect not to pay the Registration Expenses therefor pursuant to Section 2.4). For purposes of this Section 2.1(e), a Registration Statement shall not be counted if, as a result of an exercise
of the underwriter’s cut-back provisions, less than 80% of the total number of Registrable Shares that Purchasers have requested to be included in such Registration Statement are so included. 

(f) If at the time of any request to register Registrable Shares by Initiating Holders pursuant to this Section 2.1, the Company is
engaged or has plans to engage in a registered public offering or is engaged in any other activity which, in the good faith determination of the Board of Directors, would be adversely affected by the requested registration, then the Company may at
its option direct that such request be delayed for a period not in excess of 30 days from the date of such request, such right to delay a request to be exercised by the Company not more than once in any
12-month period. 
 2.2 Incidental Registration. 

(a) Whenever the Company proposes to file a Registration Statement covering shares of Common Stock (other than a Registration Statement filed
pursuant to Section 2.1) at any time and from time to time, it will, prior to such filing, give written notice to all 

  
 8 

 
Purchasers of its intention to do so. Upon the written request of a Purchaser or Purchasers given within 20 days after the Company provides such notice (which request shall state the intended
method of disposition of such Registrable Shares), the Company shall use commercially reasonable efforts to cause all Registrable Shares which the Company has been requested by such Purchaser or Purchasers to register to be registered under the
Securities Act to the extent necessary to permit their sale or other disposition in accordance with the intended methods of distribution specified in the request of such Purchaser or Purchasers; provided that the Company shall have the right to
postpone or withdraw any registration effected pursuant to this Section 2.2, prior to the effective date of such registration, without obligation to any Purchaser. The expenses of any registration withdrawn pursuant to this Section 2.2(a)
shall be borne by the Company in accordance with Section 2.4. 
 (b) If the registration for which the Company gives notice pursuant to
Section 2.2(a) is a registered public offering involving an underwriting, the Company shall so advise the Purchasers as a part of the written notice given pursuant to Section 2.2(a). In such event, (i) the right of any Purchaser to
include its Registrable Shares in such registration pursuant to this Section 2.2 shall be conditioned upon such Purchaser’s participation in such underwriting on the terms set forth herein and (ii) all Purchasers including Registrable
Shares in such registration shall enter into an underwriting agreement upon customary terms with the underwriter or underwriters selected for the underwriting by the Company. If any Purchaser who has requested inclusion of its Registrable Shares in
such registration as provided above disapproves of the terms of the underwriting, such person may elect, by written notice to the Company, to withdraw its shares from such Registration Statement and underwriting. If the managing underwriter advises
the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the shares held by holders of securities of the Company other than Purchasers and Other Holders shall be excluded from such Registration
Statement and underwriting to the extent deemed advisable by the managing underwriter, and, if a further reduction of the number of shares is required, the number of shares that may be included in such Registration Statement and underwriting shall
be allocated among all Purchasers and Other Holders requesting registration in proportion, as nearly as practicable, to the respective number of shares of Common Stock (on an as-converted basis) held by them
on the date the Company gives the notice specified in Section 2.2(a); provided that, unless such registration is in connection with the Company’s Initial Public Offering, the number of Registrable Shares permitted to be included
therein shall in any event be at least 25% of the securities included therein (based on aggregate market values). If any Purchaser or Other Holder would thus be entitled to include more shares than such holder requested to be registered, the excess
shall be allocated among other requesting Purchasers and Other Holders pro rata in the manner described in the preceding sentence. 
 (c)
Notwithstanding the foregoing, the Company shall not be required, pursuant to this Section 2.2, to include any Registrable Shares in a Registration Statement (other than in the Initial Public Offering) if such Registrable Shares can then be
sold pursuant to Rule 144(b)(1)(i) under the Securities Act. 

  
 9 

 2.3 Registration Procedures. 

(a) If and whenever the Company is required by the provisions of this Agreement to use commercially reasonable efforts to effect the
registration of any Registrable Shares under the Securities Act, the Company shall: 
 (i) file with the Commission a Registration Statement
with respect to such Registrable Shares and use commercially reasonable efforts to cause that Registration Statement to become effective as soon as possible; 

(ii) as expeditiously as possible prepare and file with the Commission any amendments and supplements to the Registration Statement and the
prospectus included in the Registration Statement as may be necessary to comply with the provisions of the Securities Act (including the anti-fraud provisions thereof) and to keep the Registration Statement effective for 12 months from the effective
date or such lesser period until all such Registrable Shares are sold; 
 (iii) as expeditiously as possible furnish to each Selling
Stockholder such reasonable numbers of copies of the Prospectus, including any preliminary Prospectus, in conformity with the requirements of the Securities Act, and such other documents as such Selling Stockholder may reasonably request in order to
facilitate the public sale or other disposition of the Registrable Shares owned by such Selling Stockholder; 
 (iv) as expeditiously as
possible use commercially reasonable efforts to register or qualify the Registrable Shares covered by the Registration Statement under the securities or Blue Sky laws of such states as the Selling Stockholders shall reasonably request, and do any
and all other acts and things that may be necessary or desirable to enable the Selling Stockholders to consummate the public sale or other disposition in such states of the Registrable Shares owned by the Selling Stockholders; provided, however,
that the Company shall not be required in connection with this paragraph (iv) to qualify as a foreign corporation or to execute a general consent to service of process in any jurisdiction or to amend its Certificate of Incorporation or By-laws, each as may be amended and/or restated from time to time, in a manner that the Board of Directors determines is inadvisable; 

(v) as expeditiously as possible, cause all such Registrable Shares to be listed on each securities exchange or automated quotation system on
which similar securities issued by the Company are then listed; 
 (vi) promptly provide a transfer agent and registrar, and provide a CUSIP
number, for all such Registrable Shares not later than the effective date of such Registration Statement; 
 (vii) promptly make available
for inspection by the Selling Stockholders, any managing underwriter participating in any disposition pursuant to such Registration Statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the Selling
Stockholders, all financial and other records, pertinent corporate documents and properties of the Company and cause the Company’s officers, directors, employees and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent in connection with such Registration Statement; 

  
 10 

 (viii) notify each Selling Stockholder, promptly after it shall receive notice thereof, of the
time when such Registration Statement has become effective or a supplement to any Prospectus forming a part of such Registration Statement has been filed; and 

(ix) as expeditiously as possible following the effectiveness of such Registration Statement, notify each seller of such Registrable Shares of
any request by the Commission for the amending or supplementing of such Registration Statement or Prospectus. 
 (b) If the Company has
delivered a Prospectus to the Selling Stockholders and after having done so the Prospectus is amended to comply with the requirements of the Securities Act, the Company shall promptly notify the Selling Stockholders and, if requested, the Selling
Stockholders shall immediately cease making offers of Registrable Shares and return all Prospectuses to the Company. The Company shall promptly provide the Selling Stockholders with revised Prospectuses and, following receipt of the revised
Prospectuses, the Selling Stockholders shall be free to resume making offers of the Registrable Shares. 
 (c) In the event that, in the
judgment of the Company, it is advisable to suspend use of a Prospectus included in a Registration Statement due to pending material developments or other events that have not yet been publicly disclosed and as to which the Company believes public
disclosure would be detrimental to the Company, the Company shall notify all Selling Stockholders to such effect, and, upon receipt of such notice, each such Selling Stockholder shall immediately discontinue any sales of Registrable Shares pursuant
to such Registration Statement until such Selling Stockholder has received copies of a supplemented or amended Prospectus or until such Selling Stockholder is advised in writing by the Company that the then current Prospectus may be used and has
received copies of any additional or supplemental filings that are incorporated or deemed incorporated by reference in such Prospectus. Notwithstanding anything to the contrary herein, the Company shall not exercise its rights under this
Section 2.3(c) to suspend sales of Registrable Shares for a period in excess of 30 days in any 365-day period. 

2.4 Allocation of Expenses. The Company will pay all Registration Expenses incurred in connection with registrations pursuant to
Sections 2.1 and 2.2 of this Agreement, regardless of whether any such registration does or does not become effective and regardless of whether such registration shall or shall not be treated as a counted registration for purposes of
Section 2.1 hereof; provided, however, that if a registration under Section 2.1 is withdrawn at the request of the Initiating Holders (other than as a result of information concerning the business or financial condition of
the Company which is made known to the Selling Stockholders after the date on which such registration was requested) and if the Initiating Holders elect not to have such registration counted as a registration requested under Section 2.1, the
Selling Stockholders shall pay the Registration Expenses of such registration pro rata in accordance with the number of their Registrable Shares included in such registration. 

  
 11 

 2.5 Indemnification and Contribution. 

(a) In the event of any registration of any of the Registrable Shares under the Securities Act pursuant to this Agreement, the Company will
indemnify and hold harmless each Selling Stockholder and the partners, members, officers, directors and stockholders of each Selling Stockholder, each underwriter of such Registrable Shares, and each other person, if any, who controls such Selling
Stockholder or underwriter within the meaning of the Securities Act or the Exchange Act against any expenses, losses, claims, damages or liabilities, joint or several, to which such Selling Stockholder, underwriter, controlling person or other
aforementioned person may become subject under the Securities Act, the Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based
upon (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, including any amendments or supplements
thereto, any preliminary prospectus or final prospectus contained in the Registration Statement, including any amendments or supplements thereto, (ii) any omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities
Act, the Exchange Act or any state securities law in connection with the Registration Statement or the offering contemplated thereby; and the Company will reimburse such Selling Stockholder, underwriter, controlling person or other aforementioned
person for any legal or any other expenses reasonably incurred by such Selling Stockholder, underwriter, controlling person or other aforementioned person in connection with investigating or defending any such loss, claim, damage, liability or
action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any untrue statement or omission made in such Registration
Statement, preliminary prospectus or prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by or on behalf of such Selling Stockholder, underwriter, controlling
person or other aforementioned person specifically for use in the preparation thereof. 
 (b) In the event of any registration of any of the
Registrable Shares under the Securities Act pursuant to this Agreement, each Selling Stockholder, severally and not jointly, will indemnify and hold harmless the Company, any other Purchaser under this Agreement selling securities in such
registration statement, each of its directors and officers and each underwriter (if any) and each person, if any, who controls the Company, such other Purchaser, or any such underwriter within the meaning of the Securities Act or the Exchange Act,
against any losses, claims, damages or liabilities, joint or several, to which the Company, such other Purchaser, such directors and officers, underwriter or controlling person may become subject under the Securities Act, Exchange Act, state
securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in
any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus contained in the Registration Statement, or any amendment or supplement to the Registration
Statement, or (ii) any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, if and to the extent (and only to the extent) that the statement

  
 12 

 
or omission was made in reliance upon and in conformity with information relating to such Selling Stockholder furnished in writing to the Company by such Selling Stockholder specifically for use
in connection with the preparation of such Registration Statement, prospectus, amendment or supplement; provided, however, that the obligations of a Selling Stockholder hereunder shall be limited to an amount equal to the net proceeds
to such Selling Stockholder of Registrable Shares sold in connection with such registration. 
 (c) Each Indemnified Party shall give notice
to the Indemnifying Party promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting
therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld, conditioned or delayed);
and, provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2.5 except to the extent that the Indemnifying
Party is adversely affected by such failure. The Indemnified Party may participate in such defense at such party’s expense; provided, however, that the Indemnifying Party shall pay such expense if the Indemnified Party reasonably
concludes that representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between the Indemnified Party and any other party represented by such
counsel in such proceeding; provided further that in no event shall the Indemnifying Party be required to pay the expenses of more than one law firm per jurisdiction as counsel for the Indemnified Party. The Indemnifying Party also
shall be responsible for the expenses of such defense if the Indemnifying Party does not elect to assume such defense. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or
litigation, and no Indemnified Party shall consent to entry of any judgment or settle such claim or litigation without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed.

 (d) In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in this
Section 2.5 is due in accordance with its terms but for any reason is held to be unavailable to an Indemnified Party in respect to any losses, claims, damages and liabilities referred to herein, then the Indemnifying Party shall, in lieu of
indemnifying such Indemnified Party, contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims, damages or liabilities to which such party may be subject in such proportion as is appropriate to reflect the
relative fault of the Company on the one hand and the Selling Stockholders on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative fault of the Company and the Selling Stockholders shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of material fact related to information supplied by the Company or
the Selling Stockholders and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Selling Stockholders agree that it would not be just and equitable
if contribution pursuant to this Section 

  
 13 

 
2.5(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of
this Section 2.5(d), (i) in no case shall any one Selling Stockholder be liable or responsible for any amount in excess of the net proceeds received by such Selling Stockholder from the offering of Registrable Shares and (ii) the Company
shall be liable and responsible for any amount in excess of such proceeds; provided, however, that no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit or proceeding against such party in respect of which
a claim for contribution may be made against another party or parties under this Section 2.5(d), notify such party or parties from whom contribution may be sought, but the omission so to notify such party or parties from whom contribution may
be sought shall not relieve such party from any other obligation it or they may have thereunder or otherwise under this Section 2.5(d). No party shall be liable for contribution with respect to any action, suit, proceeding or claim settled
without its prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. 
 (e) The rights and
obligations of the Company and the Selling Stockholders under this Section 2.5 shall survive the termination of this Agreement. 
 2.6
Other Matters with Respect to Underwritten Offerings. In the event that Registrable Shares are sold pursuant to a Registration Statement in an underwritten offering pursuant to Section 2.1, the Company agrees to (a) enter into an
underwriting agreement containing customary representations and warranties with respect to the business and operations of the Company and customary covenants and agreements to be performed by the Company, including without limitation customary
provisions with respect to indemnification by the Company of the underwriters of such offering; (b) use commercially reasonable efforts to cause its legal counsel to render customary opinions to the underwriters with respect to the Registration
Statement; and (c) use commercially reasonable efforts to cause its independent public accounting firm to issue customary “cold comfort letters” to the underwriters with respect to the Registration Statement. 

2.7 Information by Holder. Each holder of Registrable Shares included in any registration shall furnish to the Company such information
regarding such holder and the distribution proposed by such holder as the Company may reasonably request in writing and as shall be required in connection with any registration, qualification or compliance referred to in this Agreement. 

2.8 “Lock-Up” Agreement; Confidentiality of Notices. Each
Purchaser agrees, if requested by the managing underwriter of the Initial Public Offering, (i) not to (a) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Registrable Shares or other securities of the Company (excluding securities acquired in the Initial Public Offering
or in the public market after such offering) or (b) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Registrable Shares or other securities of the Company
(excluding securities acquired in the Initial Public Offering or in 

  
 14 

 
the public market after such offering), whether any transaction described in clause (a) or (b) is to be settled by delivery of securities, in cash or otherwise, during the period beginning
on the date of the filing of such registration statement with the Securities and Exchange Commission and ending 180 days after the effective date of the registration statement relating to the Initial Public Offering (plus up to an additional 34 days
to the extent requested by the managing underwriters for such offering in order to address Rule 2711(f) of the National Association of Securities Dealers, Inc. or any similar successor provision) (the
“Lock-Up Period”), provided that, all stockholders of the Company then holding at least 1% of the outstanding Common Stock (on an as-converted basis)
and all officers and directors of the Company are similarly bound, and (ii) to execute any agreement reflecting clause (i) above as may be requested by the managing underwriters at the time of such offering; provided, that all
stockholders of the Company then holding at least 1% of the outstanding Common Stock (on an as-converted basis) and all officers and directors of the Company enter into similar agreements. Notwithstanding the
foregoing, clauses (i) and (ii) above shall only be applicable to the Purchasers if all stockholders of the Company then holding at least 1% of the outstanding Common Stock (on an as-converted basis) and
all officers and directors of the Company are treated similarly with respect to any release prior to the termination of the Lock-Up period (including any extension thereof) such that if any such persons are
released, all Purchasers shall also be released to the same extent on a pro rata basis. 
 The Company may impose stop-transfer instructions
with respect to the Registrable Shares or other securities subject to the foregoing restriction until the end of such “lock-up” period. 

Any Purchaser receiving any written notice from the Company regarding the Company’s plans to file a Registration Statement, whether
pursuant to this or any other provision of this Agreement, shall treat such notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights under this Agreement. 

2.9 Limitations on Subsequent Registration Rights. The Company shall not, prior to the Initial Public Offering, without the prior
written consent of those Purchasers holding at least a majority of the Registrable Shares then held by all Purchasers, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company which
grants such holder or prospective holder rights to include securities of the Company in any Registration Statement, unless (a) such rights to include securities in a registration initiated by the Company or by Purchasers are subordinate to the
rights granted to Other Holders under Sections 2.1 and 2.2, and (b) no rights are granted to initiate a registration, other than registration pursuant to a registration statement on Form S-3 (or its
successor) in which Purchasers are entitled to include Registrable Shares on a pro rata basis with such holders based on the number of shares of Common Stock (on an as-converted basis) owned by Purchasers and
such holders. 
 2.10 Rule 144 Requirements. After the earliest of (i) the closing of the sale of securities of the Company
pursuant to a Registration Statement, (ii) the registration by the Company of a class of securities under Section 12 of the Exchange Act, or (iii) the issuance by the Company of an offering circular pursuant to Regulation A under the
Securities Act, the Company agrees to: 

  
 15 

 (a) make and keep current public information about the Company available, as those terms are
understood and defined in Rule 144; 
 (b) use commercially reasonable efforts to file with the Commission in a timely manner all reports
and other documents required of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

(c) furnish to any holder of Registrable Shares upon request (i) a written statement by the Company as to its compliance with the
reporting requirements of Rule 144 and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such
other reports and documents of the Company as such holder may reasonably request to avail itself of any similar rule or regulation of the Commission allowing it to sell any such securities without registration. 

2.11 Transfer of Registrable Shares. 

(a) Requirements for Transfer. 

(i) The Shares and the Registrable Shares shall not be sold, assigned, transferred, pledged or otherwise disposed of unless either
(A) they first shall have been registered under the Securities Act, or (B) the Company first shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is
exempt from the registration requirements of the Securities Act, and any transferee thereof has agreed in writing for the benefit of the Company to take and hold such Shares and/or Registrable Shares, as applicable, subject to, and to be bound by,
the terms and conditions set forth in this Agreement, including, without limitation, this Section 2.11. 
 (ii) Notwithstanding the
foregoing, no registration or opinion of counsel shall be required for (i) a transfer by a Purchaser to an Affiliated Party of such Purchaser, (ii) a transfer by a Purchaser which is a partnership to a partner of such partnership or a
retired partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner, or (iii) a transfer by a Purchaser which is a limited liability company to a member of such limited liability
company or a retired member who resigns after the date hereof or to the estate of any such member or retired member; provided that the transferee in each case agrees in writing to be subject to the terms of this Section 2.11 to the same extent
as if it were an original Purchaser hereunder, or (iv) a transfer made in accordance with Rule 144 under the Securities Act. 

(b) Legend. Each certificate or instrument representing (i) the Shares, or (ii) Registrable Shares shall bear a legend
substantially in the following form: 
 “The shares represented by this certificate have not been registered under the Securities Act of
1933, as amended, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such shares are registered under such Act or an opinion of counsel satisfactory to the Company is obtained to the effect that such
registration is not required. 

  
 16 

 The shares represented by this certificate may be transferred only in accordance with the terms
of an agreement between the Company and the stockholder, a copy of which is on file with the secretary of the Company.” 
 The
foregoing legend shall be removed from the certificates representing any Shares or Registrable Shares, at the request of the holder thereof, at such time as they become eligible for resale pursuant to Rule 144 under the Securities Act. 

(c) Rule 144A Information. The Company shall, at all times during which it is neither subject to the reporting requirements of
Section 13 or 15(d) of the Exchange Act, nor exempt from reporting pursuant to Rule 12g3-2(b) under the Exchange Act, upon the written request of any Purchaser, provide in writing to such Purchaser
and to any prospective transferee of any Shares or Registrable Shares of such Purchaser the information concerning the Company described in Rule 144A(d)(4) under the Securities Act (“Rule 144A Information”). The Company also
shall, upon the written request of any Purchaser, cooperate with and assist such Purchaser or any member of the National Association of Securities Dealers, Inc. PORTAL system in applying to designate and thereafter maintain the eligibility of the
Shares or Registrable Shares for trading through PORTAL. The Company’s obligations under this Section 2.11(d) shall at all times be contingent upon receipt from the prospective transferee of Shares or Registrable Shares of a written
agreement to take all reasonable precautions to safeguard the Rule 144A Information from disclosure to anyone other than persons who will assist such transferee in evaluating the purchase of any Shares or Registrable Shares. 

2.12 Termination. All of the Company’s obligations to register Shares or Registrable Shares under Sections 2.1 and 2.2 shall
terminate upon the earliest of (a) four years after the closing of a Qualified IPO, (b) the date on which all Shares or Registrable Shares may be sold within a three month period under Rule 144 or (c) a Company Sale. 

3. Right of First Refusal. 

3.1 Rights of Purchasers to Acquire Offered Securities. 

(a) The Company shall not issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange,
any Offered Securities, unless in each such case the Company shall have first complied with this Section 3.1. The Company shall deliver to each Major Investor an Offer, which shall (i) identify and describe the Offered Securities,
(ii) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (iii) identify the persons or entities (if known) to which or
with which the Offered Securities are to be offered, issued, sold or exchanged, and (iv) offer to issue and sell to or exchange with such Major Investor (A) such Major Investor’s Basic Amount and (B) such Major Investor’s
Undersubscription Amount. Notwithstanding the other provisions of this Section 3.1, after delivery of the Offer, the Company may issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange,
Offered Securities to the offerees or 

  
 17 

 
purchasers described in the Offer and upon the terms and conditions (including, without limitation, unit prices and interest rates) which are not more favorable, in the aggregate, to the
acquiring person or persons or less favorable to the Company than those set forth in the Offer without complying with the terms of this Section 3.1, provided that the Company permits each Major Investor to purchase the number of Offered
Securities that such Major Investor is entitled to purchase pursuant to this Section 3.1 on substantially the same terms as the Company sold the Offered Securities in the initial transaction, within 10 days after the Company receives a Notice
of Acceptance from such Major Investor. 
 (b) To accept an Offer, in whole or in part, a Major Investor must deliver to the Company, on or
prior to the date 15 business days after the date of delivery of the Offer, a Notice of Acceptance indicating the portion of the Major Investor’s Basic Amount that such Major Investor elects to purchase and, if such Major Investor shall elect
to purchase all of its Basic Amount, the Undersubscription Amount (if any) that such Major Investor elects to purchase. If the Basic Amounts subscribed for by all Major Investors are less than the total of all of the Basic Amounts available for
purchase, then each Major Investor who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed for, the Undersubscription Amount it has subscribed for;
provided, however, that if the Undersubscription Amounts subscribed for exceed the Available Undersubscription Amount, each Major Investor who has subscribed for any Undersubscription Amount shall be entitled to purchase only that
portion of the Available Undersubscription Amount as the Undersubscription Amount subscribed for by such Major Investor bears to the total Undersubscription Amounts subscribed for by all Purchasers, subject to rounding by the Board of Directors to
the extent it deems reasonably necessary. 
 (c) The Company shall have 90 days from the expiration of the period set forth in
Section 3.1(b) to issue, sell or exchange all or any part of the Refused Securities, but only to the offerees or purchasers described in the Offer (if so described therein) and only upon terms and conditions (including, without limitation, unit
prices and interest rates) which are not more favorable, in the aggregate, to the acquiring person or persons or less favorable to the Company than those set forth in the Offer. 

(d) In the event the Company shall propose to sell less than all the Refused Securities, then each Major Investor may, at its sole option and
in its sole discretion, reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than the number or amount of the Offered Securities that the Major Investor elected to purchase
pursuant to Section 3.1(b) multiplied by a fraction, (i) the numerator of which shall be the number or amount of Offered Securities the Company actually proposes to issue, sell or exchange (including Offered Securities to be issued or sold
to Major Investors pursuant to Section 3.1(b) prior to such reduction) and (ii) the denominator of which shall be the original amount of the Offered Securities. In the event that any Major Investor so elects to reduce the number or amount
of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the reduced number or amount of the Offered Securities unless and until such securities have again been offered to the Major Investors
in accordance with Section 3.1(a). 

  
 18 

 (e) Upon (i) the closing of the issuance, sale or exchange of all or less than all of the
Refused Securities or (ii) such other date agreed to by the Company and Major Investors who have subscribed for a majority of the Offered Securities subscribed for by the Major Investors, such Major Investor shall acquire from the Company and
the Company shall issue to such Major Investor, the number or amount of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 3.1(d) if any of the Major Investors has so elected, upon the terms and conditions
specified in the Offer. 
 (f) The purchase by the Major Investors of any Offered Securities is subject in all cases to the preparation,
execution and delivery by the Company and the Major Investors of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and substance to the Major Investors and their respective counsel. 

(g) Any Offered Securities not acquired by the Major Investors or other persons in accordance with Section 3.1(c) may not be issued, sold
or exchanged until they are again offered to the Major Investors under the procedures specified in this Agreement. 
 (h) The rights of the
Major Investors under this Section 3.1 shall not apply to: 
 (i) the issuance of any shares of Common Stock as a stock dividend to
holders of Common Stock or upon any subdivision or combination of shares of Common Stock; 
 (ii) the issuance of any shares of Common Stock
upon conversion of shares of convertible preferred stock; 
 (iii) the issuance of shares of Common Stock or options with respect thereto
(subject in either case to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events occurring after the date of this Agreement), approved by the Board of Directors, including a majority of the Preferred
Directors, issued or issuable to employees, directors or officers of, or consultants to, the Company or any Company Subsidiary pursuant to any plan, agreement or arrangement approved by the Board of Directors, including a majority of the Preferred
Directors; 
 (iv) the issuance of securities solely in consideration for the acquisition (whether by merger or otherwise) by the Company or
any Company Subsidiary of all or substantially all of the stock or assets of any other entity the terms of which are approved by the Board of Directors, including a majority of the Preferred Directors; 

(v) the issuance of shares of Common Stock by the Company in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act; 
 (vi) the issuance of shares of Common Stock, or the grant of options or warrants
therefor, in connection with any present or future borrowing, line of credit, leasing or similar financing arrangement approved by the Board of Directors and by a majority of the Preferred Directors; 

  
 19 

 (vii) the issuance of shares of Series F Preferred Stock to Additional Purchasers pursuant to
Section 2.2 of the Series F Preferred Stock Purchase Agreement; or 
 (viii) the issuance of any shares of Common Stock upon the
exercise of a Warrant. 
 (i) Notwithstanding the foregoing, the right of first offer in this Section 3 shall not be applicable to any
Major Investor with respect to any issuance of Offered Securities if (a) at the time the Company issues such Offered Securities, such Major Investor is not an “accredited investor,” as defined in Rule 501(d) of Regulation D
promulgated under the Securities Act, and (ii) such issuance of Offered Securities is only being offered by the Company to accredited investors. 

3.2 Termination. This Section 3 shall terminate upon the earlier of the closing of a Company Sale or the closing of a Qualified
IPO. 
 4. Affirmative Covenants. The Company covenants and agrees that it will perform and observe the following covenants and
provisions and will cause each Company Subsidiary to perform and observe such of the following covenants and provisions as are applicable to such Company Subsidiary: 

4.1 Payment of Taxes and Trade Debt. Pay and discharge all taxes, assessments and governmental charges or levies imposed upon it or upon
its income or profits or business, or upon any properties belonging to it, prior to the date on which penalties attach thereto, and all lawful claims, which, if unpaid, might become a lien or charge upon any properties of the Company or a Company
Subsidiary, other than those which are being contested in good faith if the Company shall have set aside on its books and shall have provided, in accordance with generally accepted accounting principles, adequate reserves with respect thereto; and
pay in conformity with customary trade terms, all lease obligations, all trade debt, and all other indebtedness incident to its operations, except such as are being contested in good faith if the Company shall have set aside on its books and shall
have provided, in accordance with generally accepted accounting principles, appropriate reserves with respect thereto. 
 4.2 Maintenance
of Insurance. Maintain with responsible and reputable insurance companies or associations, insurance in such amounts and covering such risks as the Company reasonably deems advisable. 

4.3 Preservation of Corporate Existence. Preserve and maintain its corporate existence, rights, franchises and privileges in the
jurisdiction of its incorporation, and qualify and remain qualified as a foreign corporation in each jurisdiction in which such qualification is required, unless the failure to so qualify does not and will not have a material and adverse effect on
the business, operations or financial condition of the Company; and preserve and maintain all material licenses and other rights to use patents, processes, licenses, trademarks, trade names, inventions, intellectual property rights or copyrights
owned or possessed by it as are reasonably necessary or advisable for it to conduct its business. 

  
 20 

 4.4 Compliance with Laws. Comply with all applicable laws, rules, regulations and orders
of any governmental authority, noncompliance with which could materially adversely affect its business or condition, financial or otherwise, except non-compliance being contested in good faith through
appropriate proceedings so long as the Company shall have set up and funded sufficient reserves, if any, required under generally accepted accounting principles with respect to such items. 

4.5 Keeping of Records and Books of Account. Keep adequate records and books of account, in which complete entries will be made in
accordance with generally accepted accounting principles consistently applied, reflecting all financial transactions of the Company, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization,
taxes, bad debts and other purposes in connection within its business shall be made. 
 4.6 Maintenance of Properties, etc. Maintain
and preserve all of its properties that the Company reasonably deems necessary or useful in the proper conduct of its business in good repair, working order and condition, ordinary wear and tear excepted, and from time to time make all necessary and
proper repairs, renewals, replacements, additions and improvements thereto; and comply with the provisions of all material leases to which it is a party or under which it occupies property so as to prevent any material loss or forfeiture thereof or
thereunder. 
 4.7 Inspection and Observation. 

(a) The Company shall permit any Non-Strategic Major Investor, or any authorized representative
thereof, to visit and inspect the properties of the Company, including its corporate and financial records, and to discuss its business and finances with officers of the Company, during normal business hours following reasonable notice and as often
as may be reasonably requested; provided, however, that the Company shall not be obligated pursuant to this Section 4.7 to provide access to any information which it reasonably considers to be a trade secret. 

(b) As long as S.R. One, Limited continues to be a Major Investor, the Company shall invite a representative of S.R. One, Limited to attend
all meetings of the Board of Directors in a non-voting observer capacity and, in this respect, shall give such representative all notices of its meetings and other materials as it provides to its directors,
provided, however; that the Company reserves the right to exclude such representative from executive sessions of any such meeting. Such representative as designated by S.R. One, Limited shall be subject to the approval of the Company’s Board of
Directors, acting in good faith, and shall initially be Brian Gallagher. As long as The Regents of the University of California (“UC Regents”) continues to be a Major Investor, the Company shall invite a representative of UC Regents
to attend all meetings of the Board of Directors in a non-voting observer capacity and, in this respect, shall give such representative all notices of its meetings and other materials as it provides to its
directors, provided, however; that the Company reserves the right to exclude such representative from executive sessions of any such meeting. Such representative as designated by UC Regents 

  
 21 

 
shall be subject to the approval of the Company’s Board of Directors, acting in good faith. Notwithstanding the foregoing, the Company may (i) condition the right of either of such
representatives to receive notices and other materials and to attend meetings of the Board of Directors on the execution of a confidentiality agreement provided by the Company and reasonably acceptable to such representative, but no less protective
of the Company than the applicable provisions in Section 5, and (ii) prevent either of such representatives from receiving notices and other materials and attending any portion of a meeting of the Board of Directors if the Company
reasonably determines (A) that it is necessary to do so to ensure preservation of the attorney-client privilege, (B) that it is necessary to do so to protect any trade secrets, highly confidential or proprietary information of the Company
or a third party or (C) that a real or potential conflict of interest exists or could exist between the Company and/or any of its existing or potential affiliates or business partners, and such observer or any of its respective affiliates or
business partners with regard to any subject matter included in such notice or material or to be discussed during such portion of the meeting. 

4.8 Financial Statements and Other Information. So long as any Major Investor continues to hold Shares, the Company covenants and agrees
that it will perform and observe the following covenants and provisions and will cause each Company Subsidiary to perform and observe such of the following covenants and provisions as are applicable to such Company Subsidiary: 

(a) The Company shall deliver to each Major Investor: 

(i) within 90 days after the end of each fiscal year of the Company, an audited balance sheet of the Company as at the end of such year
and audited statements of income and of cash flows of the Company for such year, certified by certified public accountants of established national reputation selected by the Company, and prepared in accordance with generally accepted accounting
principles consistently applied; and 
 (ii) within 45 days after the end of each fiscal quarter of the Company (other than the fourth
quarter), an unaudited balance sheet of the Company as at the end of such quarter, and unaudited statements of income and of cash flows of the Company for such fiscal quarter and for the current fiscal year to the end of such fiscal quarter; 

(iii) upon request of such Major Investor, within 30 days after the end of each month (other than the last month of any fiscal quarter), an
unaudited balance sheet of the Company as at the end of such month and unaudited statements of income and of cash flows of the Company for such month and for the current fiscal year to the end of such month, setting forth in comparative form the
Company’s projected financial statements for the corresponding periods for the current fiscal year; and 
 (iv) such other notices,
information and data with respect to the Company as the Company delivers to the holders of its capital stock at the same time it delivers such items to such holders. 

  
 22 

 (b) The Company shall deliver to each Non-Strategic
Major Investor, upon request of such Non-Strategic Major Investor: 
 (i) as soon as available, but
in any event prior to the commencement of each new fiscal year, a business plan and projected financial statements for such fiscal year; and 

(ii) with reasonable promptness, such other information and data as such Non-Strategic Major Investor
may from time to time reasonably request, including, but not limited to, complete capitalization charts and records of the Company. 
 (c)
The foregoing financial statements shall be prepared on a consolidated basis if the Company then has any subsidiaries. The financial statements delivered pursuant to clause (ii) of paragraph (a) and clause (i) of paragraph (b)
shall be accompanied by a certificate of the chief financial officer of the Company stating that such statements have been prepared in accordance with generally accepted accounting principles consistently applied (except as noted) and fairly present
the financial condition and results of operations of the Company at the date thereof and for the periods covered thereby. 
 (d) Upon the
request of the Strategic Major Investor, officers of the Company shall meet with representatives of the Strategic Major Investor up to two times per calendar year to discuss the Company’s business, research and finances, with the understanding
that certain information, including information that the Company reasonably determines should not be discussed for reasons of potential conflicts of interest, to protect attorney client privilege or other similar reasons, shall not be discussed at
such meetings. 
 4.9 Material Changes and Litigation. The Company shall promptly notify the Major Investors of any material adverse
change in the business, prospects, assets or condition, financial or otherwise, of the Company and of any litigation or governmental proceeding or investigation brought or, to the best of the Company’s knowledge, threatened against the Company,
or against any officer, director, key employee or principal stockholder of the Company which, if adversely determined, would have a material adverse effect on the business, prospects, assets or condition (financial or otherwise) of the Company. 

4.10 Agreements with Employees; Options. 

(a) The Company shall require (i) all persons now or hereafter employed by the Company and (ii) all independent contractors utilized
by the Company who have access to confidential or proprietary information of the Company to enter into non-disclosure and assignment of inventions agreements substantially in the form of Exhibit F or H to the
Series F Preferred Stock Purchase Agreement and shall require all persons now or hereafter employed by the Company to enter into non-competition and non-solicitation
agreements substantially in the form of Exhibit G or H to the Series F Preferred Stock Purchase Agreement, or such other form as may be approved by the Board of Directors and by a majority of the members of the Board of Directors who are not
employees of the Company or a Company Subsidiary. 
 (b) Unless otherwise approved by the Board of Directors and by a majority of the
members of the Board of Directors who are not employees of the Company or a Company Subsidiary, all options, restricted stock or similar equity grants granted or issued by the Company shall become exercisable at the rate of 25% on the first
anniversary of the date of grant and an additional 6.25% at the end of each three month period thereafter so long as the holder continues to be an employee or consultant of the Company. 

  
 23 

 (c) Prior to issuing shares of capital stock to an employee that owns, or will own following the
issuance, more than 1% of the Company’s outstanding capital stock (giving effect to conversion into Common Stock of all shares of convertible preferred stock and to the issuance of all shares of Common Stock reserved for issuance under the
employee stock plans of the Company) the Company agrees to require such employee to (i) be subject to substantially the same lock-up requirements as set forth in Section 2.8 of this Agreement and
(ii) to become a party as a Founder (as defined therein) to the Right of First Refusal and Co-Sale Agreement, as it may be amended from time to time. 

(d) Prior to issuing options or warrants to an employee that owns, or will own following the issuance, more than 1% of the Company’s
outstanding Common Stock (giving effect to the conversion into Common Stock of all shares of convertible preferred stock and to the issuance of all shares of Common Stock reserved for issuance under the employee stock plans of the Company), the
Company agrees to require such employee to be (i) subject to substantially the same lock-up requirements as set forth in Section 2.8 of this Agreement, (ii) to become a party as a Founder (as
defined therein) to the Right of First Refusal and Co-Sale Agreement, as it may be amended from time to time, and (iii) to become a party as a Founder (as defined therein) to the Voting Agreement, as it
may be amended from time to time. 
 4.11 Board of Directors. 

(a) The Company shall promptly reimburse in full each director of the Company who is not an employee of the Company for all of his or her
reasonable out-of-pocket expenses incurred in attending each meeting of the Board of Directors or any committee thereof. 

(b) The Board of Directors shall meet on at least a quarterly basis, unless otherwise agreed by a majority of the members of the Board of
Directors who are not employees of the Company or a Company Subsidiary. 
 (c) In the event that the Company or any of its successors or
assigns (i) consolidates with or merges into any other entity and shall not be the continuing or surviving corporation in such consolidation or merger or (ii) transfers or conveys all or substantially all of its properties and assets to
any entity, then, and in each such case, to the extent necessary, proper provision shall be made so that the successors and assigns of the Company assume the obligations of the Company with respect to indemnification of members of the Board of
Directors as contained in the Company’s Certificate of Incorporation, as may be amended and/or restated from time to time. 
 4.12
Related Party Transactions. 
 (a) The Company shall not enter into any agreement with any stockholder, officer or director of the
Company, or any “affiliate” of such persons (as such term is defined in the rules and regulations promulgated under the Securities Act), including without 

  
 24 

 
limitation any agreement or other arrangement providing for the furnishing of services by, rental of real or personal property from, or otherwise requiring payments to, any such person or entity,
without the consent of at least a majority of the members of the Board of Directors having no interest in such agreement or arrangement. 

(b) The approval of the Board of Directors and a majority of the members of the Board of Directors who are not employees of the Company or a
Company Subsidiary shall be required to (i) establish or increase the compensation of executive officers of the Company or (ii) grant stock options to any officer of the Company. 

4.13 Reservation of Common Stock. The Company shall reserve and maintain a sufficient number of shares of Common Stock for issuance upon
conversion of all of the outstanding Shares. 
 4.14 International Investment and Trade in Services Survey Act. The Company shall use
commercially reasonable efforts to file on a timely basis all reports required to be filed by it under 22 U.S.C. Section 3104, or any similar statute, relating to a foreign person’s direct or indirect investment in the Company. 

4.15 Standard of Conduct. The Company acknowledges receipt of the “Prevention of Corruption - Third Party Guidelines” provided
to the Company by S.R. One (the “Guidelines”). The Company agrees that it shall use commercially reasonable efforts to ensure that it and any of its subsidiaries operate its and their business in accordance with the Guidelines and shall
notify the Board of Directors if it becomes aware of any activities or proposed activities to be conducted by itself or any of its subsidiaries that may be contrary in any material respect to the principles set forth in the Guidelines. 

4.16 Prevention of Corruption. The Company shall use commercially reasonable efforts to (i) ensure that the Company and any of its
Affiliates operate to the same standards of conduct set forth in “Prevention of Corruption – Third Party Guidelines” of GlaxoSmithKline plc (“GSK”) found at:
http://www.gsk.com/policies/Prevention-of-Corruption-Third-Party-Guidelines.pdf and (ii) notify S.R. One if it becomes aware of any activities or proposed
activities to be conducted by itself or any of its Affiliates that may be contrary to GSK’s publicly announced ethical standards or the principles set forth in the “Prevention of Corruption – Third Party Guidelines” of which the
Company is aware or has been notified. 
 4.17 Use of Name. Neither the Company nor its Affiliates shall use the name of S.R. One
or GSK, or any of their respective Affiliates, in any trade publication, marketing materials or otherwise to the general public, in each case without the prior written consent of S.R. One, which consent may be withheld in its sole discretion;
provided, that (i) the parties anticipate that there will be a mutually agreed press release announcing any Closing (as defined in the Series F Preferred Stock Purchase Agreement) and (ii) following such public announcement
contemplated in clause (i), the Company may confirm that S.R. One is an investor in the Company (but not the amount or terms thereof) in a form of disclosure approved by S.R. One. 

  
 25 

 4.18 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of
Deerfield, Ponoi Capital and The Column Group (together, “TCG Funds”) and Venrock Funds, together with their respective affiliates, are professional investment funds, and as such invest in numerous portfolio companies, some of which
may be deemed competitive with the Company’s business (as currently conducted or as currently proposed to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, Deerfield, TCG Funds, and Venrock Funds shall
not be liable to the Company for any claim arising out of, or based upon, (i) the investment by Deerfield, TCG Funds, or Venrock Funds, as applicable, in any entity competitive with the Company or (ii) actions taken by any partner, officer
or other representative of Deerfield, TCG Funds, or Venrock Funds, as applicable, to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and
whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) Deerfield, TCG Funds, or Venrock Funds, as applicable, from liability associated with the unauthorized disclosure of
the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. Nothing in this Agreement shall
preclude or create an obligation or duty restricting Deerfield, TCG Funds, or Venrock Funds, as applicable, from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, whether or not such enterprise
has products or services which compete with those of the Company. 
 4.19 Termination of Covenants. Other than the covenants contained
in Sections 4.15-4.17, all covenants of the Company contained in this Section 4 shall terminate upon the earlier of the closing of a Company Sale or the closing of an Initial Public Offering. 

5. Confidentiality. Each Purchaser agrees that he, she or it will keep confidential and will not disclose, divulge or use for any
purpose, other than to monitor its investment in the Company, any Confidential Information, unless such Confidential Information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 5
by such Purchaser), (b) is or has been independently developed or conceived by the Purchaser without use of the Company’s Confidential Information or (c) is or has been made known or disclosed to the Purchaser by a third party without a
breach of any obligation of confidentiality such third party may have to the Company; provided, however, that a Purchaser may disclose Confidential Information (i) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Shares from such Purchaser as long as such prospective purchaser agrees to be
bound by the provisions of this Section 5 and is not a pharmaceutical, biotechnology or medical device company, (iii) to any Affiliated Party of such Purchaser (other than an Affiliated Party that is a pharmaceutical, biotechnology or
medical device company), provided that such party is obligated not to disclose, divulge or use any Confidential Information to the same extent as the Purchasers, or (iv) as may otherwise be required by law, provided that the Purchaser takes
reasonable steps to minimize the extent of any such required disclosure. Any Purchaser that is an investment fund may also provide summary business and financial information and milestone information to its partners, members and investors, of the
type typically provided to such partners, members and investors. Notwithstanding the foregoing, such information shall not be deemed confidential for the 

  
 26 

 
purpose of enforcing this Agreement. Each Purchaser further agrees that, except as required by law, he, she or it will not, without the prior consent of UC Regents, disclose the fact of UC
Regents’ investment in the Company or any other relationship between UC Regents and the Company to persons or entities that are not Purchasers or agents or representatives of such Purchaser (including attorneys or accountants thereof). 

6. Transfers of Rights; Calculation of Share Numbers. 

6.1 Transfer of Rights. This Agreement, and the rights and obligations of each Purchaser hereunder, may be assigned by a Purchaser to
(a) any person or entity who acquires at least 250,000 of such Purchaser’s Shares (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations, and similar events occurring after the date of this Agreement) or if
the Purchaser owns less than 250,000 Shares (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations, and similar events occurring after the date of this Agreement), then to any person or entity who acquires all of
such Purchaser’s Shares, or (b) to any Affiliated Party of such Purchaser, and, in each case, such transferee shall be deemed a “Purchaser” for purposes of this Agreement; provided that such assignment of rights shall be
contingent upon the transferee providing a written instrument to the Company notifying the Company of such transfer and assignment and agreeing in writing to be bound by the terms of this Agreement; and provided further that in no event shall the
rights under Section 4.7 and 4.8 be assigned to a pharmaceutical, biotechnology or medical device company. Notwithstanding the foregoing, any person or entity to which any Shares or Registrable Shares are transferred by a Purchaser, whether
voluntarily or by operation of law, shall be bound by the obligations under Section 2.8 to the same extent as if such transferee were a Purchaser hereunder and no Purchaser shall transfer any Shares or Registrable Shares unless the transferee
provides a written instrument to the Company notifying the Company of such transfer and agreeing in writing to be bound by the terms of Section 2.8. 

6.2 Calculation of Share Numbers. In determining the number of Shares owned by a Purchaser for purposes of exercising rights under this
Agreement, (a) Shares owned by a Purchaser shall be deemed to include Shares that have been converted into Common Stock so long as such Common Stock is owned by such Purchaser, (b) all Shares held by affiliated entities or persons shall be
aggregated together (provided that no shares shall be attributed to more than one entity or person within any such group of affiliated entities or persons) and (c) all Shares issuable to a Purchaser upon exercise of a Warrant shall be deemed
owned by such Purchaser. 
 7. General. 

7.1 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement. 
 7.2 Specific Performance. In addition to any and all other remedies that may be available
at law in the event of any breach of this Agreement, each Purchaser shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive or other equitable relief as may be granted by a
court of competent jurisdiction. 

  
 27 

 7.3 Governing Law. This Agreement shall be governed by and construed in accordance with
the General Corporation Law of the State of Delaware, as to matters within the scope thereof, and the internal laws of the Commonwealth of Massachusetts (without reference to the conflicts of law provisions thereof), as to all other matters. 

7.4 Notices. All notices, requests, consents and other communications under this Agreement shall be in writing and shall be deemed
delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next
business day delivery, in each case to the intended recipient as set forth below: 
 If to the Company, at 215 First Street, Suite 200,
Cambridge, MA 02142, Attention: President, or at such other address as may have been furnished in writing by the Company to the other parties hereto, with a copy to WilmerHale, 60 State Street, Boston, MA 02109, Attention: Lia Der Marderosian,
Esq.; or 
 If to S.R. One, Limited, at its address set forth on Exhibit A, or at such other address as may have been furnished in
writing by S.R. One, Limited to the other parties hereto, with a copy to Cooley LLP, 500 Boylston Street, Boston, MA, 02116-3736, Attention: Christian E. Plaza, Esq.; or 

If to any other Purchaser, at its address set forth on Exhibit A, or at such other address as may have been
furnished in writing by such Purchaser to the other parties hereto, with a copy to Wilson Sonsini Goodrich & Rosati PC, 650 Page Mill Road, Palo Alto, CA 94304, Attention: Kenneth Clark. 

Any party may give any notice, request, consent or other communication under this Agreement using any other means (including, without
limitation, personal delivery, messenger service, telecopy, first class mail or electronic mail), but no such notice, request, consent or other communication shall be deemed to have been duly given unless and until it is actually received by the
party for whom it is intended. Any party may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the other parties notice in the manner set forth in this Section 7.4. 

7.5 Complete Agreement. This Agreement constitutes the entire agreement and understanding of the parties hereto with respect to the
subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter, including, without limitation, the Series E-1 Investor Rights Agreement. 

7.6 Amendments and Waivers. This Agreement may be amended or terminated and the observance of any term of this Agreement may be waived
with respect to all parties to this Agreement (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and Purchasers holding Shares representing at least a majority of the
voting power of all Shares then held by Purchasers (assuming the exercise of all Warrants for shares of Common Stock); provided that any amendment, termination or waiver to the terms of Section 2 (or a defined term used therein) that occurs
after the closing of the Initial Public Offering shall instead require the written consent of 

  
 28 

 
the Company and Purchasers holding Registrable Shares representing at least 50% of the voting power of all Registrable Shares then held by all Purchasers, and any amendment, waiver, discharge or
termination of Section 4.18, or this Section 7.6 as expressly related to Deerfield, TCG Funds, or Venrock Funds, shall require the prior written consent of Deerfield, TCG Funds, or Venrock Funds, as applicable. Notwithstanding the
foregoing, this Agreement may not be amended or terminated and the observance of any term hereunder may not be waived with respect to any Purchaser without the written consent of such Purchaser unless such amendment, termination or waiver applies to
all Purchasers in the same fashion (it being agreed that a waiver of the provisions of Section 3 with respect to a particular transaction shall be deemed to apply to all Major Investors in the same fashion if such waiver does so by its terms,
notwithstanding the fact that certain Major Investors may nonetheless, by agreement with the Company, purchase securities in such transaction) without the consent of the other parties hereto, provided that, if the rights of all Major Investors under
Section 3 are waived with respect to a particular transaction without the consent of all Major Investors, and some but not all Major Investors purchase securities in such transaction, the Major Investors who did not consent to the waiver and
did not purchase securities in the transaction shall be offered the opportunity to exercise their rights under Section 3 with respect to such transaction within 30 days of the closing of such transaction. The Company shall give prompt written
notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment, termination or waiver effected in accordance with this Section 7.6
shall be binding on all parties hereto, even if they do not execute such consent. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or
continuing waiver of any such term, condition or provision. 
 7.7 Pronouns. Whenever the context may require, any pronouns used in
this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 

7.8 Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to
be an original, and all of which together shall constitute one and the same document. This Agreement may be executed by facsimile signatures. 

7.9 Section Headings and References. The section headings are for the convenience of the parties and in no way alter, modify, amend,
limit or restrict the contractual obligations of the parties. Any reference in this agreement to a particular section or subsection shall refer to a section or subsection of this Agreement, unless specified otherwise. 

  
 29 

 Executed as of the date first written above. 

 

			
	COMPANY:
	
	CONSTELLATION PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jigar Raythatha

	Name: Jigar Raythatha
	Title: President and Chief Executive Officer

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	PURCHASERS:
	
	S.R. ONE, LIMITED
		
	By:	 	 /s/ Brian M. Gallagher

	Name: Brian M. Gallagher, Jr., Ph.D.
	Title: Vice President and Partner

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	THIRD ROCK VENTURES, L.P.
		
	By:	 	Third Rock Ventures GP, L.P.,
		 	its general partner
		
	By:	 	TRV GP, LLC,
		 	its general partner
		
	By:	 	 /s/ Robert Tepper

	Name: Robert Tepper
	Title: Partner

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	TOPSPIN BIOTECH FUND II, LP
		
	By:	 	 /s/ Leo A. Guthart

	Name: Leo A. Guthart
	Title: Managing Director
	
	TOPSPIN FUND LP
		
	By:	 	 /s/ Leo A. Guthart

	Name: Leo A. Guthart
	Title: Managing Director
	
	MSSB C/F LEO A GUTHART
		
	By:	 	 /s/ Leo A. Guthart

	Name: Leo A. Guthart
	Title: Managing Director

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	THE COLUMN GROUP, LP
	
	By: The Column Group GP, LP
	Its: General Partner
	By: The Column Group, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name: James Evangelista
	Title: Chief Financial Officer
	
	PONOI CAPITAL, L.P.
	
	By: Ponoi Management, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name: James Evangelista
	Title: Chief Financial Officer

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
		
	By:	 	 /s/ Jagdeep Singh Bachher

	Name: Jagdeep Singh Bachher
	Title: Chief Investment Officer

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	VENROCK ASSOCIATES V, L.P.
	By: Venrock Management V, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory
	
	VENROCK PARTNERS V, L.P.
	By: Venrock Partners Management V, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name; David L. Stepp
	Authorized Signatory
	
	VENROCK ENTREPRENEURS FUND V, L.P.
	By: VEF Management V, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	CASDIN PARTNERS MASTER FUND LP
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Partner
	
	CASDIN VENTURE OPPORTUNITIES FUND, L.P.
	
	By: Casdin Venture Opportunities Fund GP, LLC,
		 	its General Partner
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Partner

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	ALEXANDRIA VENTURE INVESTMENTS, LLC, a Delaware limited liability company
	
	 By: Alexandria Real Estate Equities, Inc.,

a Maryland corporation, managing member

		
	By:	 	 /s/ Aaron Jacobson

	Name: Aaron Jacobson
	Title: VP – Corporate Counsel

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	SPUR VENTURES II, L.P.
		
	By:	 	 /s/ Paul D. Fetsch

	Name: Paul D. Fetsch
	Title: Member of General Partner

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	SM CP LLC
		
	By:	 	 /s/ Ronald Sinacore

	Name: Ronald Sinacore
	Title: Manager

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	GRANT AND JEANNETTE HEIDRICH COMMUNITY PROPERTY TRUST, U/D/T 8/84
		
	By:	 	 /s/ Grant Heidrich

	Name: Grant Heidrich
	Title: Trustee
	
	HEIDRICH FAMILY PARTNERS I
		
	By:	 	 /s/ Grant Heidrich

	Name: Grant Heidrich
	Title: General Partner

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	DAVID V. AND ALENA Z. GOEDDEL 2004 TRUST
		
	By:	 	 /s/ David V. Goeddel

	Name: David V. Goeddel
	Title: Trustee
		
	By:	 	 /s/ Alena V. Goeddel

	Name: Alena V. Goeddel
	Title: Trustee

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	MERITZ NS GLOBAL BIO FUND
	
	By: Meritz Securities Co., Ltd.
	Its: Co-managing general partner
		
	By:	 	 /s/ Song Min-Kyu

	Name: Song Min-Kyu
	Title: Deputy General Manager
	
	By: NS Investment Co., Ltd.
	Its: Co-managing general partner
		
	By:	 	 /s/ Tae-Kyoung Sohn

	Name: Tae-Kyoung Sohn
	Title: Managing Director
	
	By: Paratus Investment Co., Ltd.
	Its: Co-managing general partner
		
	By:	 	 /s/ Chan-Ho Lee

	Name: Lee, Chan-Ho
	Title: Managing Director

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.
	
	By: VHCP Management II, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory
	
	VHCP CO-INVESTMENT HOLDINGS II, LLC
	
	By: VHCP Management II, LLC
	Its: Manager
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	CORMORANT PRIVATE HEALTHCARE FUND I, LP
		
	By:	 	 /s/ Bihua Chen

	By: Cormorant Private Healthare GP, LLC
	By: Bihua Chen, Managing Member of the GP
	
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
		
	By:	 	 /s/ Bihua Chen

	By: Cormorant Global Healthcare GP, LLC
	By: Bihua Chen, Managing Member of the GP
	
	CRMA SPV, L.P.
		
	By:	 	 /s/ Bihua Chen

	By: Cormorant Asset Management, LLC
	By: Bihua Chen, CEO/CIO
	Its: Attorney-in-Fact

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	PRECISION ONCO LIMITED
		
	By:	 	 /s/ Yuan Sun

	Name: Yuan Sun
	Title: Director

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	HH CTL HOLDINGS LIMITED
		
	By:	 	 /s/ Colm John O’Connell

	Name: Colm John O’Connell
	Title: Director

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
	
	By: Deerfield Mgmt, L.P.
		 	General Partner
	
	By: J.E. Flynn Capital, LLC
		 	General Partner
		
	By:	 	 /s/ David J. Clark

	Name: David J. Clark
	Title: Authorized Signatory

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	ORBIMED PRIVATE INVESTMENTS VI, LP
	
	By: OrbiMed Capital GP VI LLC,
		 	its General Partner
	
	By: OrbiMed Advisors LLC
		 	its Managing Member
		
	By:	 	 /s/ Carl L. Gordon

	Name: Carl L. Gordon
	Title: Member
	
	ORBIMED GLOBAL HEALTHCARE MASTER FUND, L.P.
	
	By: OrbiMed Global Healthcare GP LLC,
		 	its General Partner
	
	By: OrbiMed Advisors LLC,
		 	its Managing Member
		
	By:	 	 /s/ Carl L. Gordon

	Name: Carl L. Gordon
	Title: Member

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	PONOI CAPITAL II, LP
	
	By: Ponoi II Management, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name: James Evangelista
	Title: Chief Financial Officer

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	FIDELITY MT. VERNON STREET TRUST:
	FIDELITY SERIES GROWTH COMPANY FUND
		
	By:	 	 /s/ Colm Hogan

	Name: Colm Hogan
	Title: Authorized Signatory
	
	FIDELITY MT. VERNON STREET TRUST:
	FIDELITY GROWTH COMPANY FUND
		
	By:	 	 /s/ Colm Hogan

	Name: Colm Hogan
	Title: Authorized Signatory
	
	FIDELITY GROWTH COMPANY COMMINGLED POOL
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	 /s/ Colm Hogan

	Name: Colm Hogan
	Title: Authorized Signatory

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 
			
	MOUNTAIN BERG LIMITED
		
	By:	 	 /s/ Nick Teagle

	Name: Nick Teagle
	Title: Director

  
 [Signature Page to
Fifth Amended and Restated Investor Rights Agreement] 

 AMENDMENT TO THE 

FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This Amendment to the Fifth Amended and Restated Investor Rights Agreement (the “Amendment”) is made as of the 21st day of June, 2018, by and among Constellation Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and the other signatories hereto. Capitalized terms used and not
otherwise defined herein shall have the meanings ascribed to such terms in the Fifth Amended and Restated Investor Rights Agreement, dated as of March 22, 2018, by and among the Corporation and the investors identified therein (the
“IRA”). 
 RECITALS: 

WHEREAS, the Corporation and the other signatories hereto desire to amend the IRA to expand the definition of Registrable Shares; and 

WHEREAS, pursuant to Subsection 7.6 of the IRA, the IRA may be amended with the written consent of the Corporation and the holders of a
majority of the Shares currently outstanding (collectively, the “Requisite Parties”); and 
 WHEREAS, in accordance with
Subsection 7.6 of the IRA, this Amendment applies to all Investors in the same fashion. 
 NOW THEREFORE, in consideration of the mutual
covenants contained herein and for other valuable consideration, the receipt of which is hereby acknowledged, the parties hereto, constituting the Requisite Parties, agree as follows: 

1. Amendment of Section 1 of the IRA. Section 1 of the IRA is hereby amended by deleting the
definition of “Registrable Shares” in its entirety and replacing it with the following: 
 “Registrable Shares”
means (a) the shares of Common Stock issued or issuable upon conversion of the Shares, (b) any other shares of Common Stock, and any shares of Common Stock issued or issuable upon the conversion or exercise of any other securities of the
Company, held by the Investors as of the date hereof, and (c) any other shares of Common Stock issued in respect of such shares (because of stock splits, stock dividends, reclassifications, recapitalizations or similar events); provided,
however, that shares of Common Stock which are Registrable Shares shall cease to be Registrable Shares (i) upon any sale pursuant to a Registration Statement or Rule 144 under the Securities Act or (ii) upon any sale in any
manner to a person or entity which is not entitled, pursuant to Section 6, to the rights under this Agreement or (iii) at such time, following an Initial Public Offering, as they become eligible for sale pursuant to Rule 144(b)(1)(i) under
the Securities Act. Wherever reference is made in this Agreement to a request or consent of holders of a certain percentage of Registrable Shares, the determination of such percentage shall include shares of Common Stock issuable upon conversion of
the Shares (including Shares issuable upon the exercise of outstanding Warrants) even if such conversion has not been effected. 

 2. Governing Law. This Amendment shall be governed by the internal law of
the State of Delaware. 
 3. Counterparts. This Amendment may be executed in two (2) or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal
ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

4. Entire Agreement. The IRA (including the Exhibits thereto), as supplemented and modified by this Amendment, the
Amended and Restated Certificate of Incorporation of the Corporation, the Fifth Amended and Restated Stockholders’ Voting Agreement, and Fifth Amended and Restated Right of First Refusal and Co-Sale
Agreement constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is
expressly cancelled. 
 5. Remaining Provisions of the IRA. Except as provided herein, each of the other provisions of
the IRA shall remain in full force and effect. 
 6. References. Upon the effectiveness of this Amendment, on and
after the date hereof, each reference in the IRA to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the IRA, as amended hereby. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to the Fifth Amended and Restated
Investor Rights Agreement as of the date first written above. 
  

			
	CORPORATION:
	CONSTELLATION PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jigar Raythatha

	Name: Jigar Raythatha
	Title: President and Chief Executive Officer

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to the Fifth Amended and Restated
Investor Rights Agreement as of the date first written above. 
  

			
	HOLDERS OF REGISTRABLE SHARES:
	
	THE COLUMN GROUP, LP
	
	By: The Column Group GP, LP Its: General Partner
	By: The Column Group, LLC Its: General Partner
		
	By:	 	 /s/ Peter Svennilson

	Name: Peter Svennilson
	Title: Managing Partner
	
	PONOI CAPITAL, L.P.
	
	By: Ponoi Management, LLC
	Its: General Partner
		
	By:	 	 /s/ Peter Svennilson

	Name: Peter Svennilson
	Title: Managing Partner
	
	PONOI CAPITAL II, L.P.
	
	By: Ponoi II Management, LLC
	Its: General Partner
		
	By:	 	 /s/ Peter Svennilson

	Name: Peter Svennilson
	Title: Managing Partner

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	THIRD ROCK VENTURES, L.P.
	
	 By: Third Rock Ventures GP, L.P.,
its genera1 partner

	
	 By: TRV GP, LLC,
its genera1 partner

		
	By:	 	 /s/ Robert Tepper

	Name: Robert Tepper
	Title: Partner

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	VENROCK ASSOCIATES V, L.P.
	By: Venrock Management V, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory 
	
	VENROCK PARTNERS V, L.P.
	By: Venrock Partners Management V, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory 
	
	VENROCK ENTREPRENEURS FUND V, L.P.
	By: VEF Management V, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.
	
	By: VHCP Management II, LLC
	Its: General Partner
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory 
	
	VHCP CO-INVESTMENT HOLDINGS II, LLC
	By: VHCP Management II, LLC
	Its: Manager
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Authorized Signatory

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	TOPSPIN BIOTECH FUND II, LP
		
	By:	 	 /s/ Steven J. Winick

	Name: Steven J. Winick
	Title: Managing Director 
	
	TOPSPIN FUND LP
		
	By:	 	 /s/ Steven J. Winick

	Name: Steven J. Winick
	Title: Managing Director 

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
		
	By:	 	 /s/ Jagdeep Singh Bachher

	Name: Jagdeep Singh Bachher
	Title: Chief Investment Officer

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
	
	CORMORANT PRIVATE HEALTHCARE FUND I, LP
	
	By: /s/ Bihua
Chen                                    
	By: Cormorant Private Healthare GP, LLC
	 By: Bihua Chen, Managing Member of the GP
  

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

	
	By: /s/ Bihua
Chen                                    
	By: Cormorant Global Healthcare GP, LLC
	 By: Bihua Chen, Managing Member of the GP
  

CRMA SPV, L.P.

	
	By: /s/ Bihua
Chen                                    
	By: Cormorant Asset Management, LLC
	By: Bihua Chen, CEO/CIO
	Its: Attorney-in-Fact

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	S.R. ONE LIMITED
		
	By:	 	 /s/ Brian M. Gallagher

	Name: Brian M. Gallagher, Jr., Ph.D.
	Title: Vice President and Partner

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	PRECISION ONCO LIMITED
		
	By:	 	 /s/ Yuan Sun

	Name: Yuan Sun
	Title: Director

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	CASDIN VENTURE OPPORTUNITIES FUND, L.P.

 
			
	
	 By: Casdin Venture Opportunities Fund GP, LLC,

       its General Partner

 
			
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Member

 
			
	
	CASDIN PARTNERS MASTER FUND, L.P.

 
			
	
	 By: Casdin Partners GP, LLC,

       its General Partner

 
			
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Member

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	DAVID V. AND ALENA Z. GOEDDEL 2004 TRUST
		
	By:	 	 /s/ David V. Goeddel

	Name: David V. Goeddel
	Title: Trustee
		
	By:	 	 /s/ Alena V. Goeddel

	Name: Alena V. Goeddel
	Title: Trustee

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	ERIK V. GOEDDEL IRREVOCABLE TRUST
		
	By:	 	 /s/ Robert T. Stenson

	Name: Robert T. Stenson
	Title: Trustee
	
	TYLER D. GOEDDEL IRREVOCABLE TRUST
		
	By:	 	 /s/ Robert T. Stenson

	Name: Robert T. Stenson
	 Title: Trustee

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	ALEXANDRA VENTURES INVESTMENTS, LLC, a Delaware limited liability company
	
	By: Alexandria Real Estate Equities, Inc, a Maryland corporation, managing member
		
	By:	 	 /s/ Aaron Jacobson

	 Name: Aaron Jacobson

	 Title: SVP – Venture Counsel

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
			
	ALTITUDE LIFE SCIENCE VENTURES, L.P.
		
	By:	 	 /s/ David Maki

	Name: David Maki
	Title: Managing Partner

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement] 

 
	
	 MERITZ NS GLOBAL BIO FUND
  

By Meritz Securities Co., Ltd.
 Its: Co-managing general
partner

	
	/s/ Min-Kye Song
	 Name: Min-Kye Song
 Title: Deputy General
Manager

  

	
	 By NS Investment Co., Ltd.
 Its: Co-managing
general partner

	
	/s/ Tae-Kyoung Sohn
	 Name: Tae-Kyoung Sohn
 Title: Managing
Director

  

	
	 By Paratus Investment Co., Ltd.
 Its:
Co-managing general partner

	
	/s/ Chan-Ho Lee
	 Name: Chan-Ho Lee
 Title: Managing
Director

 [Signature Page to Amendment to Fifth Amended and Restated Investor Rights Agreement]EX-10.5

 Exhibit 10.5 

CONSTELLATION PHARMACEUTICALS, INC. 

2018 EQUITY INCENTIVE PLAN 
 1.
Purpose 
 The purpose of this 2018 Equity Incentive Plan (the “Plan”) of Constellation Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important
contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except
where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of
1986, as amended, and any regulations thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as
determined by the Board of Directors of the Company (the “Board”). 
 2. Eligibility 

All of the Company’s employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and
advisors are defined and interpreted for purposes of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), or any successor form) are eligible to be granted
Awards under the Plan. Each person who is granted an Award under the Plan is deemed a “Participant.” “Award” means Options (as defined in Section 5), SARs (as defined in Section 6),
Restricted Stock (as defined in Section 7), Restricted Stock Units (as defined in Section 7) and Other Stock-Based Awards (as defined in Section 8). 

3. Administration and Delegation 
 (a)
Administration by Board of Directors. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it
shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in
the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board’s sole discretion and shall be final and binding on all persons having or
claiming any interest in the Plan or in any Award. 
 (b) Appointment of Committees. To the extent permitted by applicable law, the
Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a “Committee”). All references in the Plan to the “Board” shall mean the Board or a
Committee of the Board or the officers referred to in Section 3(c) to the extent that the Board’s powers or authority under the Plan have been delegated to such Committee or officers. 

 (c) Delegation to Officers. Subject to any requirements of applicable law (including as
applicable Sections 152 and 157(c) of the General Corporation Law of the State of Delaware), the Board may delegate to one or more officers of the Company the power to grant Awards (subject to any limitations under the Plan) to employees or officers
of the Company and to exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix the terms of Awards to be granted by such officers, the maximum number of shares subject to Awards that the officers
may grant, and the time period in which such Awards may be granted; and provided further, that no officer shall be authorized to grant Awards to any “executive officer” of the Company (as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) or to any “officer” of the Company (as defined by Rule
16a-1(f) under the Exchange Act). 
 4. Stock Available for Awards 

(a) Number of Shares; Share Counting. 

(1) Authorized Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan (any or all of which
Awards may be in the form of Incentive Stock Options, as defined in Section 5(b)) for up to such number of shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”) as is equal to the sum
of: 
 (A) 30,600,000 shares of Common Stock; plus 

(B) such additional number of shares of Common Stock (up to 31,671,207 shares) as is equal to the sum of (x) the number of shares of
Common Stock reserved for issuance under the Company’s Amended and Restated 2008 Stock Incentive Plan, as amended, (the “Existing Plan”) that remain available for grant under the Existing Plan immediately prior to the
effectiveness of the registration statement for the Company’s initial public offering and (y) the number of shares of Common Stock subject to awards granted under the Existing Plan which awards expire, terminate or are otherwise
surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code); plus 

(C) an annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2019 and
continuing for each fiscal year until, and including, the fiscal year ending December 31, 2028, equal to the least of (i) 24,400,000 shares of Common Stock, (ii) 4% of the outstanding shares on such date and (iii) an amount determined by
the Board. 
 Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. 

(2) Share Counting. For purposes of counting the number of shares available for the grant of Awards under the Plan: 

  
 -2- 

 (A) all shares of Common Stock covered by SARs shall be counted against the number of shares
available for the grant of Awards under the Plan; provided, however, that (i) SARs that may be settled only in cash shall not be so counted and (ii) if the Company grants an SAR in tandem with an Option for the same number of shares
of Common Stock and provides that only one such Award may be exercised (a “Tandem SAR”), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in
connection with the other’s exercise will not restore shares to the Plan; 
 (B) if any Award (i) expires or is terminated,
surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a
contractual repurchase right) or (ii) results in any Common Stock not being issued (including as a result of an SAR that was settleable either in cash or in stock actually being settled in cash), the unused Common Stock covered by such Award
shall again be available for the grant of Awards; provided, however, that (1) in the case of Incentive Stock Options, the foregoing shall be subject to any limitations under the Code, (2) in the case of the exercise of an SAR, the
number of shares counted against the shares available under the Plan shall be the full number of shares subject to the SAR multiplied by the percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such
SAR upon exercise and (3) the shares covered by a Tandem SAR shall not again become available for grant upon the expiration or termination of such Tandem SAR; and 

(C) shares of Common Stock delivered (by actual delivery, attestation, or net exercise) to the Company by a Participant to (i) purchase
shares of Common Stock upon the exercise of an Award or (ii) satisfy tax withholding obligations with respect to Awards (including shares retained from the Award creating the tax obligation) shall be added back to the number of shares available
for the future grant of Awards. 
 (b) Substitute Awards. In connection with a merger or consolidation of an entity with the Company
or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on
such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section 4(a)(1), except as may be
required by reason of Section 422 and related provisions of the Code. 
 (c) Limit on Awards to
Non-Employee Directors. The maximum value of (i) shares of Common Stock subject to Awards granted in any calendar year to any individual non-employee director
(calculated based on grant date fair value for financial reporting purposes) plus (ii) the cash retainer paid in any calendar year to any individual non-employee director shall not exceed $600,000 in the
case of an incumbent director or $900,000 in the case of a new director during his or her first year of service. The Board may make exceptions to this limit for individual non-employee directors in
extraordinary circumstances, as the Board may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award such
compensation. 

  
 -3- 

 5. Stock Options 

(a) General. The Board may grant options to purchase Common Stock (each, an “Option”) and determine the number
of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as
it considers necessary or advisable. 
 (b) Incentive Stock Options. An Option that the Board intends to be an “incentive stock
option” as defined in Section 422 of the Code (an “Incentive Stock Option”) shall only be granted to employees of Constellation Pharmaceuticals, Inc., any of Constellation Pharmaceuticals, Inc.’s present or
future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be
construed consistently with the requirements of Section 422 of the Code. An Option that is not intended to be an Incentive Stock Option shall be designated a “Non-Qualified
Option.” The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an
Incentive Stock Option to a Non-Qualified Option. 
 (c) Exercise Price. The Board shall
establish the exercise price of each Option or the formula by which such exercise price will be determined. The exercise price shall be specified in the applicable Option agreement. The exercise price shall be not less than 100% of the Grant Date
Fair Market Value (as defined below) of the Common Stock on the date the Option is granted; provided that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not
less than 100% of the Grant Date Fair Market Value on such future date. “Grant Date Fair Market Value” of a share of Common Stock for purposes of the Plan will be determined as follows: 

(1) if the Common Stock trades on a national securities exchange, the closing sale price (for the primary trading session) on the date of
grant; or 
 (2) if the Common Stock does not trade on any such exchange, the average of the closing bid and asked prices on the date of
grant as reported by an over-the-counter marketplace designated by the Board; or 

(3) if the Common Stock is not publicly traded, the Board will determine the Grant Date Fair Market Value for purposes of the Plan using any
measure of value it determines to be appropriate (including, as it considers appropriate, relying on appraisals) in a manner consistent with the valuation principles under Code Section 409A, except as the Board may expressly determine
otherwise. 
 For any date that is not a trading day, the Grant Date Fair Market Value of a share of Common Stock for such date will be determined by using
the closing sale price or average of the bid and asked prices, as appropriate, for the immediately preceding trading day and with the timing in the formulas above adjusted accordingly. The Board can substitute a particular time of day or other
measure of “closing sale price” or “bid and asked prices” if appropriate because of exchange or market procedures or can, in its sole discretion, use weighted averages either on a daily basis or such longer period as complies
with Code Section 409A. 

  
 -4- 

 The Board has sole discretion to determine the Grant Date Fair Market Value for purposes of the Plan, and all
Awards are conditioned on the Participants’ agreement that the Board’s determination is conclusive and binding even though others might make a different determination. 

(d) Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may
specify in the applicable option agreement; provided, however, that no Option will be granted with a term in excess of 10 years. 

(e) Exercise of Options. Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic)
approved by the Company, together with payment in full (in the manner specified in Section 5(f)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by
the Company as soon as practicable following exercise. 
 (f) Payment Upon Exercise. Common Stock purchased upon the exercise of an
Option granted under the Plan shall be paid for as follows: 
 (1) in cash or by check, payable to the order of the Company; 

(2) except as may otherwise be provided in the applicable Option agreement or approved by the Board, by (i) delivery of an irrevocable and
unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and
unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

(3) to the extent provided for in the applicable Option agreement or approved by the Board, by delivery (either by actual delivery or
attestation) of shares of Common Stock owned by the Participant valued at their fair market value (valued in the manner determined by (or in a manner approved by) the Board), provided (i) such method of payment is then permitted under
applicable law, (ii) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board and (iii) such Common Stock is not subject to any
repurchase, forfeiture, unfulfilled vesting or other similar requirements; 
 (4) to the extent provided for in the applicable Non-Qualified Option agreement or approved by the Board, by delivery of a notice of “net exercise” to the Company, as a result of which the Participant would receive (i) the number of shares
underlying the portion of the Option being exercised, less (ii) such number of shares as is equal to (A) the aggregate exercise price for the portion of the Option being exercised divided by (B) the fair market value of the Common
Stock (valued in the manner determined by (or in a manner approved by) the Board) on the date of exercise; 

  
 -5- 

 (5) to the extent permitted by applicable law and provided for in the applicable Option agreement
or approved by the Board by payment of such other lawful consideration as the Board may determine; or 
 (6) by any combination of the above
permitted forms of payment. 
 (g) Limitation on Repricing. Unless such action is approved by the Company’s stockholders, the
Company may not (except as provided for under Section 9): (1) amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option,
(2) cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section 4(b)) covering the same or a different number of shares
of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option, (3) cancel in exchange for a cash payment any outstanding Option with an exercise price per share above the
then-current fair market value of the Common Stock (valued in the manner determined by (or in the manner approved by) the Board) or (4) take any other action under the Plan that constitutes a “repricing” within the meaning of the
rules of the NASDAQ Stock Market (“NASDAQ”). 
 6. Stock Appreciation Rights 

(a) General. The Board may grant Awards consisting of stock appreciation rights (“SARs”) entitling the holder,
upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of Common
Stock (valued in the manner determined by (or in the manner approved by) the Board) over the measurement price established pursuant to Section 6(b). The date as of which such appreciation is determined shall be the exercise date. 

(b) Measurement Price. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The
measurement price shall not be less than 100% of the Grant Date Fair Market Value of the Common Stock on the date the SAR is granted; provided that if the Board approves the grant of an SAR effective as of a future date, the measurement price
shall be not less than 100% of the Grant Date Fair Market Value on such future date. 
 (c) Duration of SARs. Each SAR shall be
exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; provided, however, that no SAR will be granted with a term in excess of 10 years. 

(d) Exercise of SARs. SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic)
approved by the Company, together with any other documents required by the Board. 

  
 -6- 

 (e) Limitation on Repricing. Unless such action is approved by the Company’s
stockholders, the Company may not (except as provided for under Section 9): (1) amend any outstanding SAR granted under the Plan to provide a measurement price per share that is lower than the then-current measurement price per share of such
outstanding SAR, (2) cancel any outstanding SAR (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section 4(b)) covering the same or a different
number of shares of Common Stock and having an exercise or measurement price per share lower than the then-current measurement price per share of the cancelled SAR, (3) cancel in exchange for a cash payment any outstanding SAR with a
measurement price per share above the then-current fair market value of the Common Stock (valued in the manner determined by (or in a manner approved by) the Board) or (4) take any other action under the Plan that constitutes a
“repricing” within the meaning of the rules of NASDAQ. 
 7. Restricted Stock; Restricted Stock Units 

(a) General. The Board may grant Awards entitling recipients to acquire shares of Common Stock (“Restricted
Stock”), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event
that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to
receive shares of Common Stock or cash to be delivered at the time such Award vests or is settled (“Restricted Stock Units”) (Restricted Stock and Restricted Stock Units are each referred to herein as a “Restricted
Stock Award”). 
 (b) Terms and Conditions for All Restricted Stock Awards. The Board shall determine the terms and
conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. 

(c) Additional Provisions Relating to Restricted Stock. 

(1) Dividends. Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash, stock or property)
declared and paid by the Company with respect to shares of Restricted Stock (“Accrued Dividends”) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and
forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month
following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock. 

(2) Stock Certificates. The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as
dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods,
the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to his or her Designated Beneficiary. “Designated Beneficiary” means
(i) the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death or (ii) in the absence of an effective
designation by a Participant, the Participant’s estate. 

  
 -7- 

 (d) Additional Provisions Relating to Restricted Stock Units. 

(1) Settlement. Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock
Unit, the Participant shall be entitled to receive from the Company such number of shares of Common Stock or (if so provided in the applicable Award agreement) an amount of cash equal to the fair market value (valued in the manner determined by (or
in a manner approved by) the Board) of such number of shares of Common Stock as are set forth in the applicable Restricted Stock Unit agreement. The Board may provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis
or at the election of the Participant in a manner that complies with Section 409A of the Code. 
 (2) Voting Rights. A
Participant shall have no voting rights with respect to any Restricted Stock Units. 
 (3) Dividend Equivalents. The Award agreement
for Restricted Stock Units may provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (“Dividend
Equivalents”). Dividend Equivalents may be settled in cash and/or shares of Common Stock and shall be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid, in each case
to the extent provided in the Award agreement. 
 8. Other Stock-Based Awards 

(a) General. The Board may grant other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by
reference to, or are otherwise based on, shares of Common Stock or other property (“Other Stock-Based Awards”). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards
granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. 

(b) Terms and Conditions. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other
Stock-Based Award, including any purchase price applicable thereto. 
 9. Adjustments for Changes in Common Stock and Certain Other Events 

(a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the
number and class of securities available under the Plan, (ii) the share counting rules and sublimits set forth in Sections 4(a) and 4(c), (iii) the number and class of securities and exercise price per share of each outstanding

  
 -8- 

 
Option, (iv) the share and per-share provisions and the measurement price of each outstanding SAR, (v) the number of shares subject to and the
repurchase price per share subject to each outstanding award of Restricted Stock and (vi) the share and per-share-related provisions and the purchase price, if any, of each outstanding Restricted Stock
Unit award and each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the
event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of
the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the
shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. 

(b) Reorganization Events. 

(1) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with or
into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common
Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 

(2) Consequences of a Reorganization Event on Awards Other than Restricted Stock. 

(A) In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion
of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant):
(i) provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that all of
the Participant’s unvested Awards will be forfeited immediately prior to the consummation of such Reorganization Event and/or unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised
by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii) provide that outstanding Awards shall become exercisable, realizable or deliverable, or restrictions applicable to an Award
shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share
surrendered in the Reorganization Event (the “Acquisition Price”), make or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (A) the number of shares of Common Stock
subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the Acquisition Price over
(II) the exercise, 

  
 -9- 

 
measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v) provide that, in connection with a liquidation or
dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi) any combination of the
foregoing. In taking any of the actions permitted under this Section 9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically. 

(B) Notwithstanding the terms of Section 9(b)(2)(A), in the case of outstanding Restricted Stock Units that are subject to
Section 409A of the Code: (i) if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a “change in control event”, then no assumption or substitution shall be permitted pursuant to Section 9(b)(2)(A)(i) and
the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii) the Board may only undertake the actions set forth in clauses (iii), (iv) or (v) of
Section 9(b)(2)(A) if the Reorganization Event constitutes a “change in control event” as defined under Treasury Regulation Section 1.409A-3(i)(5)(i) and such action is permitted or
required by Section 409A of the Code; if the Reorganization Event is not a “change in control event” as so defined or such action is not permitted or required by Section 409A of the Code, and the acquiring or succeeding
corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i) of Section 9(b)(2)(A), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event
without any payment in exchange therefor. 
 (C) For purposes of Section 9(b)(2)(A)(i), an Award (other than Restricted Stock) shall be
considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the
consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the
consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the
consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for
the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determines to be equivalent
in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. 

 

  
 -10- 

 (3) Consequences of a Reorganization Event on Restricted Stock. Upon the occurrence of a
Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company’s successor and shall, unless the
Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such Restricted
Stock; provided, however, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the
Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted
Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied. 

10. General Provisions Applicable to Awards 

(a) Transferability of Awards. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant,
either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant,
shall be exercisable only by the Participant; provided, however, that, except with respect to Awards subject to Section 409A of the Code, the Board may permit or provide in an Award for the gratuitous transfer of the Award by the
Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Common Stock subject to such Award to such proposed transferee; provided further, that the Company shall not be required to recognize any
such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound
by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section 10(a) shall
be deemed to restrict a transfer to the Company. 
 (b) Documentation. Each Award shall be evidenced in such form (written, electronic
or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. 
 (c)
Board Discretion. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly.

 (d) Termination of Status. The Board shall determine the effect on an Award of the disability, death, termination or other
cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal representative,
conservator, guardian or Designated Beneficiary, may exercise rights under the Award. 

  
 -11- 

 (e) Withholding. The Participant must satisfy all applicable federal, state, and local or
other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may elect to satisfy the withholding obligations through
additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash
equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price,
unless the Company determines otherwise. If provided for in an Award or approved by the Committee, a Participant may satisfy the tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock,
including shares retained from the Award creating the tax obligation, valued at their fair market value (valued in the manner determined by (or in a manner approved by) the Company); provided, however, except as otherwise provided by the
Committee, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal, state and local
tax purposes, including payroll taxes, that are applicable to such supplemental taxable income), except that, to the extent that the Company is able to retain shares of Common Stock having a fair market value (determined by, or in a manner approved
by, the Company) that exceeds the statutory minimum applicable withholding tax without financial accounting implications or the Company is withholding in a jurisdiction that does not have a statutory minimum withholding tax, the Company may retain
such number of shares of Common Stock (up to the number of shares having a fair market value equal to the maximum individual statutory rate of tax (determined by, or in a manner approved by, the Company)) as the Company shall determine in its sole
discretion to satisfy the tax liability associated with any Award. Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. 

(f) Amendment of Award. Except as otherwise provided in Sections 5(g) and 6(e) with respect to repricings and Section 11(d) with
respect to actions requiring stockholder approval, the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or
realization, and converting an Incentive Stock Option to a Non-Qualified Option. The Participant’s consent to such action shall be required unless (i) the Board determines that the action, taking
into account any related action, does not materially and adversely affect the Participant’s rights under the Plan or (ii) the change is permitted under Section 9. 

(g) Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to
remove restrictions from shares previously issued or delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company’s counsel, all other
legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations and (iii) the
Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

  
 -12- 

 (h) Acceleration. The Board may at any time provide that any Award shall become
immediately exercisable in whole or in part, free from some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. 

11. Miscellaneous 
 (a) No Right To
Employment or Other Status. No person shall have any claim or right to be granted an Award by virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any
other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the
applicable Award. 
 (b) No Rights As Stockholder; Clawback Policy. Subject to the provisions of the applicable Award, no Participant
or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be issued with respect to an Award until becoming the record holder of such shares. In accepting an Award under the Plan, a Participant
agrees to be bound by any clawback policy the Company has in effect or may adopt in the future. 
 (c) Effective Date and Term of
Plan. The Plan shall become effective immediately prior to the effectiveness of the Company’s registration statement for its initial public offering (the “Effective Date”). No Awards shall be granted under the Plan
after the expiration of 10 years from the Effective Date, but Awards previously granted may extend beyond that date. 
 (d) Amendment of
Plan. The Board may amend, suspend or terminate the Plan or any portion thereof at any time provided that no amendment that would require stockholder approval under the rules of NASDAQ may be made effective unless and until the Company’s
stockholders approve such amendment. In addition, if at any time the approval of the Company’s stockholders is required as to any other modification or amendment under Section 422 of the Code or any successor provision with respect to
Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section 11(d) shall apply to, and be
binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of
Participants under the Plan. No Award shall be made that is conditioned upon stockholder approval of any amendment to the Plan unless the Award provides that (i) it will terminate or be forfeited if stockholder approval of such amendment is not
obtained within no more than 12 months from the date of grant and (2) it may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval. 

  
 -13- 

 (e) Authorization of Sub-Plans (including for Grants
to non-U.S. Employees). The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other
laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i) such limitations on the Board’s discretion under the Plan as the Board deems
necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each
supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. 

(f) Compliance with Section 409A of the Code. If and to the extent (i) any portion of any payment, compensation
or other benefit provided to a Participant pursuant to the Plan in connection with his or her employment termination constitutes “nonqualified deferred compensation” within the meaning of Section 409A of the Code and (ii) the
Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees
that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of “separation from service” (as determined under Section 409A
of the Code) (the “New Payment Date”), except as Section 409A of the Code may then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of
separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule. 

The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments,
compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not to satisfy the conditions of that section. 

(g) Limitations on Liability. Notwithstanding any other provisions of the Plan, no individual acting as a director,
officer, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be
personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee or agent of the Company. The Company will indemnify and hold harmless each director,
officer, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys’ fees) or liability (including any
sum paid in settlement of a claim with the Board’s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person’s own fraud or bad faith. 

(h) Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the
laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than
the State of Delaware. 

  
 -14-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]